Clinical and Genetic Predictors of Aromatase Inhibitor-Induced Arthralgia by Borrie, Adrienne Elizabeth
Western University 
Scholarship@Western 
Electronic Thesis and Dissertation Repository 
7-25-2018 2:00 PM 
Clinical and Genetic Predictors of Aromatase Inhibitor-Induced 
Arthralgia 
Adrienne Elizabeth Borrie 
The University of Western Ontario 
Supervisor 
Kim, Richard B. 
The University of Western Ontario 
Graduate Program in Physiology and Pharmacology 
A thesis submitted in partial fulfillment of the requirements for the degree in Doctor of 
Philosophy 
© Adrienne Elizabeth Borrie 2018 
Follow this and additional works at: https://ir.lib.uwo.ca/etd 
 Part of the Medical Pharmacology Commons 
Recommended Citation 
Borrie, Adrienne Elizabeth, "Clinical and Genetic Predictors of Aromatase Inhibitor-Induced Arthralgia" 
(2018). Electronic Thesis and Dissertation Repository. 5590. 
https://ir.lib.uwo.ca/etd/5590 
This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted 
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of 
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca. 
i 
 
Abstract 
Aromatase inhibitors (AIs) are the most commonly used first-line endocrine treatment for 
postmenopausal women with estrogen receptor-positive breast cancer. Significant 
adverse drug reactions are associated with AIs, the most common being arthralgia. We 
hypothesized that a comprehensive assessment of pharmacogenetic and clinical variables 
that affect AI tolerability could improve AI selection and treatment for breast cancer 
patients. We recruited 196 patients diagnosed with breast cancer initiating AI therapy at 
the London Regional Cancer Program. Patients completed questionnaires regarding 
arthralgia symptoms and provided blood samples at baseline, 2 months and 6 months 
after AI initiation. Plasma letrozole drug concentration was measured by liquid 
chromatography tandem-mass spectrometry (LC-MS/MS). DNA was extracted and used 
for pharmacogenetic analysis. More than half of patients had increases in pain and 
stiffness in their hands, shoulders, and arms, hips and knees. A LC-MS/MS analysis 
demonstrated that plasma concentrations of letrozole were negatively associated with 
body mass index (P = 0.0003) and positively associated with age (P = 0.0430). CYP2A6 
genotype was significantly associated with letrozole levels (P < 0.0001), and increased 
plasma letrozole levels were observed in patients with CYP2A6 reduced-function 
genotypes. However, letrozole concentration level and CYP2A6 genotype were not 
significantly associated with a change in pain score from baseline. Further 
pharmacogenetic investigations revealed that four SNPs within the estrogen synthesis and 
metabolism pathway, namely, CYP19A1 (rs4775936) and ESR1 (rs9322336, rs2234693, 
rs930799), were associated with the development of arthralgia. CYP19A1 (rs4775936) 
was also a significant predictor of discontinuation of drug. Finally, we found that a SNP 
 
ii 
 
within the vitamin D pathway CYP27B1 (rs4646536) was associated with an increase in 
pain in the hands, arms, and shoulders. Patients who had a vitamin D level of at least 
50ng/ml were found to be four times less likely to develop AI arthralgia. Understanding 
the impact of genes and drug levels on AI-induced arthralgia will help clinicians better 
manage AI therapy. This work will facilitate personalized medicine for women with 
breast cancer and advance understanding of endocrine biology.   
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1.1 Introduction 
Breast cancer is the most common cancer among Canadian women and second only to 
lung cancer as a leading cause of death from cancer in Canadian women [1]. Breast 
cancer is a heterogeneous group of diseases with subtypes that are characterized by 
different clinical, molecular, genetic, histological, and prognostic characteristics [2]. 
Several different types of neoplasms arise from the cells in the breast. Most breast 
cancers are adenocarcinonomas, which are tumours that originate in a gland cell. The 
most common adenocarcinomas of the breast are ductal carcinoma, which begins in the 
milk ducts, and lobular carcinoma, which starts in the lobules. Both men and women 
have breast tissue but women have a much larger amount and a much higher risk for 
breast cancer; less than 1% of all breast cancers occur in men [1]. 
1.2 Characterization of breast cancer 
When a patient with breast cancer is first diagnosed, their disease is described by stage, 
grade, and molecular subtype. Stage describes the anatomical extent of the tumour within 
the body and is typically expressed as a number on a scale of 0 through IV. Stage is based 
on the TNM (tumour, node, metastasis) system describing the size and extent of the 
primary of the tumour, whether the cancer has spread to the regional lymph nodes, and 
whether the cancer has spread to other areas of the body (metastasis). Grade is a score 
based on visual assessment of cell morphology and architecture, and indicates how 
quickly the cells are dividing and if the organization and morphology of the cells are 
abnormal [3]. Typically, less differentiated and higher grade tumours are more 
biologically aggressive. 
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Breast cancer is also characterized by immunohistochemical and molecular subtypes, and 
these subtypes have distinct pathological features as well as clinical implications. 
Traditionally, breast cancers were classified as tumours that expressed the estrogen 
receptor (ER-positive breast cancer) and those that did not (ER-negative breast cancer) 
[4]. Early studies found that tumours in which the ER and progesterone receptor (PR) 
were present were distinct from the more aggressive ER/PR-negative tumours that had a 
less favourable prognosis. Human epidermal growth factor receptor 2 (HER2) is a protein 
found to be overexpressed in approximately 15-30% of breast cancers and is associated 
with more aggressive disease and poorer prognosis [5, 6]. ER, PR and HER2 can all be 
measured by immunohistochemistry [7]. The four major molecular subtypes first 
identified by Perou and colleagues are luminal A, luminal B, HER2-type, and basal-like 
[8, 9]. Luminal A tumours are characterized by higher expression of ER (ER-positive), 
normal expression of HER2 (HER2-negative), low histological grade, and are associated 
with a favourable prognosis. Luminal A tumours have low levels of the protein Ki-67, a 
cellular marker for proliferation. Approximately 50-70% of all breast cancers are luminal 
A tumours, making it the most common subtype [10]. Luminal B tumours make up 
approximately 10-20% of breast cancers and this subtype is characterized by high 
expression of ER, high levels of Ki-67, normal or high expression of HER2, as well as 
intermediate histological grade and larger tumour size. Luminal B tumours tend to have a 
relatively good prognosis, though not as favourable as luminal A tumours [10]. HER2-
type tumours are characterized by intermediate to high histological grade, are ER-
negative, predominately HER2-positive, and account for 15-20% of breast cancers. 
HER2-type breast cancer has a poorer prognosis than the luminal subtypes. However, 
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treatment with HER2 targeted therapies such as trastuzumab (Herceptin) may improve 
outcomes [10, 11]. Basal-like tumours, which make up approximately 10-15% of all 
breast cancers, tend to be ER, PR, and HER2-negative, and therefore, they are also 
known as triple negative breast cancer. Basal-like tumours are the most aggressive form 
of breast cancer and have the poorest prognosis [10]. These four subtypes were identified 
based on gene expression patterns in tumor samples from patients with locally advanced 
breast cancer and were confirmed using microarray expression profiling in a separate 
patient cohort [8, 12]. Perou et al. also identified a fifth subtype, called normal-like, 
which resembled the features of luminal A. However, this subtype was later hypothesized 
to be a technical artifact thought to arise from contamination of samples with normal 
mammary cells, and is not widely accepted as an official subtype [13]. Heterogeneous 
expression of the estrogen, progesterone, and HER2 receptors has been observed among 
different patients with breast cancer, as well as between matched samples from primary 
tumours and their metastases. Patient treatment is planned based on factors such as 
tumour size, grade, and molecular subtype. Table 1.1 summarizes the four major types of 
breast cancer, their features, and their indicated treatments [14-16]. 
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Table 1.1 Summary of breast tumour molecular subtypes 
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1.3 Estrogen 
Estrogen is an important hormone and signalling molecule best known for its role in 
female reproduction, but is also involved in male reproduction as well as playing a 
significant function in the immune, neuroendocrine, skeletal, and vascular systems of 
both males and females [17]. Estrogen acts as a mediator in multiple physiological 
pathways and has been implicated in the development and progression of diseases such as 
cancer, cardiovascular disease, osteoporosis, obesity, and endometriosis [18]. It is well 
established that estrogen is an essential mediator in the development of breast tissue in 
females during puberty and pregnancy [19, 20]. Epithelial cells in the breast respond to 
estrogen signalling through its receptor, estrogen receptor alpha (ERα), and progesterone 
signalling through PR. Estrogen stimulates the development of tubules into the ductal 
system of the breasts, the growth of stromal tissue, and the accumulation of adipose 
tissue. Estrogen is a pivotal driver of ductal growth and elongation during breast 
development [21, 22]. 
Estrogen also plays an important role in breast cancer; there is considerable evidence 
linking estrogen exposure with an increased risk of breast cancer. While no clear 
mechanism through which estrogen induces breast cancer has been found, one possible 
pathway is that of estrogen binding to ERα and inducing breast cell proliferation through 
its direct and indirect actions on the enhanced production of growth factors [23]. A longer 
duration of estrogen exposure, through early menarche and late menopause, is known to 
lead to an increased risk of developing breast cancer [24].  
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There are two major types of estrogen in postmenopausal women – estrone and estradiol. 
Aromatase is an enzyme transcribed from the CYP19A1 gene that catalyzes estrogen 
biosynthesis through the conversion of testosterone to estradiol and androstenedione to 
estrone (Figure 1.1) [25, 26]. While estrogen is produced in the ovaries and adipose tissue 
in premenopausal women, among postmenopausal women, adipose tissue is considered to 
be the major source of estrogen synthesis[27]. Aromatase is expressed across multiple 
human tissues including the ovaries, testes, adipose tissue, brain, muscle, skin fibroblasts 
and osteoblasts of bone[28]. Therefore, use of aromatase inhibitors (AIs) results in 
reduced formation of estrogens, thus lowering the amount of circulating estrogens and 
thereby reduce ER-dependent cellular proliferation [29]. 
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Figure 1.1 Estrogen synthesis and interaction with aromatase inhibitors 
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1.4 Estrogen receptor 
Estrogenic effects largely occur as a consequence of the activation of the two forms of 
the ER, ERα and ERβ, upon binding with estrogen [30]. When a tumour is classified as 
ER+ or ER-, it is the ERα that is present. ERα, encoded by the ESR1 gene, is activated by 
estrogen binding [31], resulting in increased cell proliferation. Thus, expression of ERα 
has been proposed as a possible mechanism for the initiation of breast cancer. The ERβ is 
encoded by the ESR2 gene, but its role is less well understood [32]. Both ERα and ERβ 
are widely expressed across many tissues. Figure 1.2 illustrates how estrogen acts as a 
ligand to initiate estrogen receptor signaling, which regulates the expression of multiple 
target genes [17].  
Though estrogen effects are primarily mediated by ERα and ERβ, a G protein estrogen 
receptor, (GPER) also mediates estrogen action in both normal and malignant cells [33]. 
GPER, also known as GPR30, is localized on the cell membrane and the endoplasmic 
reticulum. It is expressed in a variety of tissues including the breast and the blood vessel 
endothelium, and is involved in regulating breast development and vasodilation [34, 35]. 
Until 2005, GPER was considered an orphan receptor, however recent studies have 
shown that its’ stimulation may play an important role in cell proliferation and cancer cell 
invasion [36]. Currently there are no large clinical studies evaluating GPER expression in 
ER-positive breast cancer, though this could be an area that is addressed in the future. 
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Figure 1.2 Signalling of the estrogen receptor in breast cancer 
1) Estrogen binds with high affinity and 2) changes the shape of the receptor. 3) Specific 
sites are activated, and in this state, the receptors can combine to form dimers. 4) The 
dimers translocate into the nucleus and 5) bind to discrete DNA sequences called 
estrogen response elements (ERE). Co-activators are recruited, and this results in RNA 
polymerase. 
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1.5 Breast cancer in postmenopausal women 
Approximately 80% of breast cancers occur in postmenopausal women. While 
menopause is not a risk factor for breast cancer, the risk of developing cancer increases 
with age [37]. Obesity is also associated with a significantly elevated risk of breast cancer 
[38] and a poor prognosis among postmenopausal breast cancer patients [39, 40]. In 
postmenopausal women, estrogen is no longer produced by the ovaries but is still 
synthesized in many tissues, with adipose tissue becoming the main source of estrogen. 
Other estrogen-producing tissues include skin, muscle, and healthy and malignant breast 
tissue [26]. Increased fat tissue leads to higher estrogen levels, which can increase breast 
cancer risk [24]. 
1.6 Breast Cancer Treatment 
Breast cancer treatment is prescribed by an oncologist and is based on the molecular 
subtype, size, node status, and grade of the tumour, as well as the age, sex, and 
menopausal status of the patient [41]. Surgery and radiation therapy are localized 
regional treatments used to target the cancer at the tumour site. Surgery involves the 
removal of the cancer tissues and a small amount of healthy tissue surrounding the 
tumour, while radiation therapy ablates cancer cells using high-energy radiation. Breast 
cancer may also be treated with systematic treatments that include chemotherapy, 
endocrine therapy, and biological therapy [41]. 
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1.6.1 Endocrine therapy 
Over a century ago, the discovery that ovarian ablation may precipitate tumour regression 
in premenopausal women marked the beginning of endocrine-based treatment of breast 
cancer [42]. The approval of tamoxifen, a selective estrogen receptor modulator, for 
breast cancer in 1977 led to a marked improvement in survival for ER-positive breast 
cancer. The next advance in endocrine therapy came with the aromatase inhibitors (AIs), 
letrozole, anastrozole, and exemestane, whose chemical structures are depicted in Figure 
1.3. These therapies improved 10-year survival rates and decreased the risk of disease 
relapse in postmenopausal women with breast cancer over treatment with tamoxifen [43, 
44]. Today, endocrine-based therapy is prescribed to women with ER/PR-positive breast 
cancer based on their menopausal status and cancer relapse risk. Endocrine therapy slows 
or stops cancer growth by disrupting the signalling of ERα in the case of tamoxifen, or by 
reducing the available estrogen to cancer cells in the case of AIs. Tamoxifen is primarily 
used to treat pre-menopausal women, although it can also be used to treat post-
menopausal women, and AIs are used to treat post-menopausal women. Because AIs 
interfere with the conversion of androgens into estrogens in peripheral tissues (skin, 
muscle, fat, and benign and malignant breast tissue), they are only capable of lowering 
estrogen production outside of the ovaries and are therefore only prescribed to post-
menopausal women [26, 45]. 
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Figure 1.3 Chemical structures of the aromatase inhibitors 
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1.6.2 Aromatase inhibitors 
Currently, letrozole, anastrozole, and exemestane, are the most commonly prescribed AIs 
for the treatment of women with ER+ breast cancer. Lowering estrogen causes the 
tumour growth to be reduced, and limits disease progression and recurrence [46-48]. AIs 
block the activity of aromatase by binding to the enzyme either reversibly, as in the case 
of letrozole and anastrozole, or irreversibly, as in the case of exemestane. Letrozole and 
anastrozole are known to competitively bind to the AI substrate-binding site, prevent 
binding of androgens, thus limiting the catalytic conversion of androgens to estrogen. 
Exemestane binds irreversibly to the AI active site to inactivate the enzyme commonly 
referred to as “suicide inhibition” [49]. All three AIs potently reduce estrogen below the 
level that can be detected using most of the current clinical assays [50]. Letrozole inhibits 
approximately 99% of estrogen biosynthesis, while anastrozole has an inhibition rate of 
97%, and exemestane inhibits 98% of estrogen biosynthesis [51]. It should be noted that 
AIs are typically prescribed for 5 years, usually after adjuvant chemotherapy, surgery, 
and/or radiation, although it can be prescribed as a monotherapy for early stages of breast 
cancer. AIs may also be prescribed for 2-3 years following 2-3 years of tamoxifen 
therapy [46-48]. While aromatase inhibitors greatly reduce estrogen levels, 
dihydrotestosterone, total testosterone, androstenedione, DHEA, or free androgen index 
levels are not affected [52]. 
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1.6.2.1 Letrozole 
Letrozole, also known by the trade name Femara, is a non-steroidal aromatase inhibitor 
that binds reversibly to the aromatase enzyme and blocks the conversion of androgen to 
estrogen via competitive inhibition. It is prescribed as a standard oral dose of 2.5mg daily 
for five years, and its absorption is not affected by food [53]. It has a terminal half-life of 
48h and steady-state plasma concentration is reached in 2-6 weeks [53] although some 
studies have shown that it may take up to 8 weeks to reach steady-state concentration 
[54]. Maximal estrogen suppression of greater than 90% is reached within 14 days of the 
drug start date [55].  
 
1.6.2.2 Anastrozole 
Anastrozole, also known as Arimidex, is a non-steroidal aromatase inhibitor, which like 
letrozole, reversibly binds to the aromatase enzyme and blocks estrogen production 
through competitive inhibition [56]. Anastrozole has a standard daily oral dose of 1mg 
for a total treatment duration of five years. The terminal half-life of anastrozole is 46 
hours, and plasma concentrations reach steady-state levels at approximately 7 days [56]. 
Maximal estrogen suppression of greater than 90% is achieved within 2-4 days of daily 
1mg dosage [57]. 
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1.6.2.3 Exemestane 
Exemestane, also known by the brand name Aromasin, is a steroidal aromatase inhibitor 
structurally related to androstenedione, and it binds to the active site of aromatase 
enzyme irreversibly, resulting in inactivation by suicide inhibition. Exemestane is given 
at a daily oral dose of 25mg for five years, has a terminal half-life of 24 hours, and 
reaches steady-state concentration level by 7 days [58, 59]. 
1.6.3 Adverse drug reactions associated with AIs 
Meta-analysis and cross-trial comparisons of the three AIs have shown that they have 
similar adverse drug reaction (ADR) profiles across the drug class [60, 61]. The most 
common ADRs are arthralgia and joint symptoms, which affect up to 50% of patients 
[62, 63]. Significantly, up to 30% of patients on AIs will discontinue their use due to 
ADRs, and 75% report the cause of discontinuation is arthralgia [64]. Other common 
ADRs include hot flashes and night sweats, fatigue, loss of bone mineral density, loss of 
sex drive, and vaginal dryness or itching. Less frequent ADRs include thinning of the 
hair, increased blood pressure, increased cholesterol, and cognitive effects such as mood 
swings and depression. Due to the androgenic structure of exemestane, it is known to 
give rise to hormonal effects apart from the decrease in estrogen production and is 
sometimes associated with weight gain and acne [58]. Letrozole and anastrozole have a 
non-steroidal molecular structure and therefore do not have the same androgenic, 
progestogenic, or estrogenic ADRs as exemestane [65]. 
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1.6.4 Aromatase inhibitor induced arthralgia 
AIs are effective for treating breast cancer, but they may have unwanted musculoskeletal 
effects, including joint pain (arthralgia) and muscle pain (myalgia) [62, 66, 67]. This 
adverse effect is often referred to as AI-associated musculoskeletal syndrome.  Arthralgia 
and myalgia are widely regarded as the most common and pervasive adverse drug 
reactions reported by patients treated with AIs. AI-induced arthralgia presents in patients 
with joint pain, typically affecting the wrists, hands, shoulders, hips and knees [62]. AI-
induced arthralgia often compromises quality of life and lead to non-adherence of the 
drug. Other less common adverse drug reactions include thinning of the bones or 
osteoporosis, vaginal dryness, vaginal bleeding, and loss of libido [68-70]. Patients who 
experience AI-induced arthralgia find that these symptoms typically appear within the 
first month of drug initiation and worsen in the second and third months of drug use [71]. 
AI-induced arthralgia is resistant to treatment with NSAIDs, opioids, and other pain 
medications [72]. 
It is difficult to pinpoint the exact prevalence of AI-induced arthralgia for a variety of 
reasons. Within the literature that describes AI-induced arthralgia, there is not a 
consistent definition relating to severity or types of pain. Furthermore, the largest clinical 
trials of AIs were not designed to capture and examine arthralgia. In a 5-year study that 
compared anastrozole to tamoxifen, the prevalence of arthralgia in breast cancer patients 
on anastrozole was 35% [73]. A large randomized study of more than 4,000 patients, 
which compared patients on exemestane to patients on tamoxifen, reported that the 
prevalence of arthralgia was only 5% in patients taking exemestane [46]. However, 
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another similarly powered study of exemestane in post-menopausal women found that 
30% of patients had arthralgia [74]. The rates of arthralgia vary greatly when measured 
by patient self-reporting. However, studies that were specifically designed to measure the 
prevalence of AI-induced arthralgia, found the rates are consistently higher, and closer to 
50% of patients. One study of 200 women on AIs utilized a 25-item questionnaire 
designed to assess joint symptoms and found that 47% of women developed AI-related 
joint pain and 44% developed AI-related stiffness [62].  
Currently, the mechanism that underlies AI-induced arthralgia is largely unknown, 
although there is a growing body of literature that suggests there may be multiple 
intersecting mechanisms. Patient variability in AI metabolism and drug levels, the rate of 
estrogen decline during AI treatment, vitamin D deficiency, and increased muscle and 
joint inflammation have all been associated with arthralgia (Table 1.2). Links between 
these factors suggest an interplay of complex mechanisms (Figure 1.4).  
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Figure 1.4 An overview of proposed mechanisms for AI arthralgia 
Associated genes are depicted in grey. Associated biomarkers are depicted in black. 
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Table 1.2 Gene variants involved in AI arthralgia 
Select variants and variant effects within estrogen metabolism genes 
ESR1     
     rs2234693  upstream SNP In vivo Currently unknown [85] 
     rs9340799  intronic SNP In vivo Currently unknown [85] 
     rs9322336 intronic SNP In vivo Currently unknown [86] 
CYP17A1     
     rs4919686 a SNP In vivo Currently unknown [79] 
     rs4919683 a SNP In vivo Currently unknown [79] 
     rs4919687 a SNP In vivo Currently unknown [79] 
     rs3781287 a SNP In vivo Currently unknown [79] 
     rs10786712 a SNP In vivo Currently unknown [79] 
     rs6163 synonymous SNP In vivo Currently unknown [79] 
     rs743572 a SNP In vivo Currently unknown [79] 
CYP19A1     
     rs60271534 repeat polymorphism (intron 4) In vivo Currently unknown [81] 
     Haplotype M_3_5  haplotype of 14 SNPs In vivo Currently unknown [82] 
     rs4775936 intronic SNP In vivo Currently unknown [79] 
Select variants and variant effects within genes which regulate inflammation 
OPG     
     rs2073618 a SNP In vivo Currently unknown [78, 83] 
TCL1A     
    rs11849538 a functional SNP In vivo and  
in vitro 
studies 
Creates an estrogen response element  [92, 93] 
Select variants and variant effects within aromatase inhibitor metabolism genes 
CYP2A6     
     CYP2A6*2  
     (rs1801272) 
a SNP In vivo results in less than 40% CYP2A6 
activity  
[99] 
     CYP2A6*4 a whole deletion of gene In vivo results in no CYP2A6 activity [99] 
     CYP2A6*9  
     (rs28399433) 
a SNP In vivo results in 40-50% CYP2A6 activity [99] 
     CYP2A6*12 a translocation In vivo results in 40-50% CYP2A6 activity [99] 
CYP3A4     
     CYP3A4*22  
     (rs35599367) 
a SNP In vivo and  
in vitro 
studies 
associated with low CYP3A4 activity [104] 
CYP3A5     
     CYP3A5 *3  
     (rs35599367) 
a SNP In vivo and  
in vitro 
studies 
associated with lower clearance of drugs 
metabolized by the gene product of 
CYP3A5 
[105] 
UGT2B17     
     Deletion a whole deletion of gene In vivo and  
in vitro 
studies 
decreases 17-hydroexemestane 
glucuronidation process by 14 times,  
effecting both metabolism and excretion 
of the active metabolite 
[106] 
Select variants and variant effects within Vitamin D metabolism/pathway genes 
VDR     
     rs11568820 a SNP in a cdx-2-binding site in 
the VDR promoter and can  
modulate gene expression levels 
In vivo and  
in vitro 
studies 
in vitro study that rs11568820 alleles 
have different transcriptional activities  
[79] 
CYP27B1     
     rs4646536 SNP in intronic region In vivo Currently unknown [79] 
     rs10877012 SNP in promoter region In vivo Currently unknown [79] 
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1.7 Estrogen deprivation and metabolism 
As early as 1925, loss of estrogen in women was noted to link with arthralgia [75]. There 
is also evidence to suggest that the sudden decline in estrogen levels, rather than simply a 
low estrogen state, stimulates arthralgia. In a large study of over 2000 women, 41% of 
peri-menopausal women presented with increased joint pain and stiffness, while only 
25% of pre-menopausal women and 29% of post-menopausal women had these same 
symptoms [76]. Furthermore, the Women’s Health Initiative found that estrogen 
replacement therapy improves arthralgia and joint health in post-menopausal women 
[77]. A study of 420 post-menopausal breast cancer patients, all on AIs, found that mean 
estradiol levels were significantly lower in patients with AI arthralgia than in patients 
without AI arthralgia [78]. 
1.7.1 Estrogen synthesis (CYP17A1 and CYP19A1) 
CYP17A1 (also known as 17α-hydroxylase) and CYP19A1 (also known as aromatase) 
are the key enzymes that both play pivotal roles in estrogen synthesis. Specifically, 
CYP17A1 adds a hydroxyl group to both pregnenolone and progesterone, and then 
further converts them to androstenedione. Aromatase catalyzes the final step of 
converting androstenedione to estrone (Figure 1.1).   
A clinical study of postmenopausal women with breast cancer on AIs found an 
association between AI arthralgia and several single nucleotide polymorphisms (SNPs) in 
CYP17A1 (rs4919686, rs4919683, rs4919687, rs3781287, rs10786712, rs6163, rs743572) 
[79].  
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CYP19A1 is highly polymorphic, with more than 88 known SNPs, including at least 4 
non-synonymous SNPs [80]. Variation in the CYP19A1 gene, specifically a 
tetranucleotide repeat polymorphism in intron 4 (rs60271534), has been shown to alter 
levels of estrone and estradiol in patients on AI therapy. In the same study, patients who 
carry at least one 8-repeat allele had a lower risk of developing AI arthralgia [81]. 
Another study which focused on haplotypes within CYP19A1 found that AI arthralgia 
was significantly and strongly associated with haplotype M_3_5, which contained the 
following 14 SNPs: rs12148604, rs4646, rs10046, rs700519, rs4324076, rs700518, 
rs3759811, rs727479, rs4775936, rs10459592, rs767199, rs10519297, rs1062033, 
rs2008691, rs1008805, and rs17523527 [82]. However, a subsequent study of 154 
patients on AIs failed to replicate the association with AI arthralgia when they tested 6 
SNPs from haplotype M_3_5 (rs10046, rs700519, rs700518, rs727479, rs4775936, 
rs10459592) [83]. When Garcia-Giralt et al. tested two of the SNPs included in haplotype 
M_3_5 (rs4775936 and rs1062033) in a study of 343 postmenopausal women on AIs, 
they did not find that either SNP alone predicted AI arthralgia. However, one of the 
haplotype M_3_5 SNPs, rs4775936, was associated with worsening pain [79]. 
1.7.2 Estrogen receptor 1 (ESR1) 
Estrogen receptor alpha (ERα) is encoded by ESR1 and is an important member of a 
nuclear hormone receptor superfamily. ERα is responsible for mediating the effects of 
estrogens and because it is expressed in ER-positive breast tumours and drives 
proliferation of breast cancer cells, thus it is the primary target of endocrine therapies 
[84]. A clinical study of patients on AI therapy found that two SNPs in the ESR1 gene 
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(rs2234693 and rs9340799) were associated with AI arthralgia [85]. [85]. rs2234693 is a 
SNP located upstream of ESR1 and is also known as the -397T>C variation. rs9340799 is 
located in an intronic region of ESR1. A large study of patients on letrozole and 
exemestane demonstrated an association between ESR1 SNP rs9322336 and 
discontinuation of AI therapy due to musculoskeletal toxicity; however, this effect was 
only present for the patients on exemestane [86]. Further replication and functional 
validation of these 3 SNPs are needed.  
1.8 Potential role of Inflammation in AI-arthralgia 
Arthralgia is often caused by inflammation within the muscles and joints, and 
inflammatory cytokines are linked to estrogen levels in the body. Specifically, higher 
levels of estrogen suppress inflammatory cytokine production, while lower estrogen 
levels increase their production [87].  Specific inflammatory cytokines such as tumor 
necrosis factor-α (TNF-α), interleukin-1 (IL-1) have been detected in peri-menopausal 
women and found at higher concentrations in the synovial fluid of joints, which may 
contribute to inflammation and pain [88]. As AIs suddenly and markedly deplete estrogen 
in treated patients, this rapid lowering of estrogen may be part of the mechanism of AI-
induced arthralgia.  
However, the evidence to support a direct effect of lower estrogen levels to arthralgia is 
somewhat conflicting. A recent study of 30 cases with AI arthralgia and 22 controls 
without AI arthralgia measured changes in serum concentrations of inflammatory 
molecules, including IL-1, interleukin-6 (IL-6), and TNF-α [89]. Contrary to previous 
reports, this study found no statistically significant differences in serum concentrations 
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for any of the inflammatory biomarker between cases and controls. In fact, for 6 of 36 
factors, baseline measurements of serum concentration levels were significantly lower in 
cases than controls. One of the limitations of this study was that inflammatory molecules 
were measured systemically, whereas inflammation may be occurring locally at the 
joints. A study that used magnetic resonance imaging was able to demonstrate 
tenosynovial and articular changes in patients who developed AI arthralgia in their hands 
and wrists, suggesting active inflammation in the actual joints or tissues around the joint 
[90]. 
1.8.1 Osteoprotegerin and RANKL in AI arthralgia 
Osteoprotegerin is a cytokine receptor and a member of the TNF receptor superfamily. 
Recent studies have found an association between a SNP (rs2073618) in osteoprotegerin 
(OPG) gene and AI arthralgia [78, 83]. OPG is a receptor for a ligand called receptor 
activator of nuclear factor kappa-B ligand (RANKL). When OPG binds to RANKL, it 
prevents nuclear factor kappa B (NF-κB) activation, which is a key transcription factor 
for immune-related genes, and a known regulator of inflammatory response [91].  
1.8.2 T-cell leukemia 1A (TCL1A) 
Variation in the TCL1A gene was identified to be associated with AI-arthralgia in a 
genome-wide association study (GWAS) that included 293 cases with AI-arthralgia and 
585 controls. Four SNPs close to TCL1A were found to be the most significantly 
associated with AI arthralgia (P = 2.23E-06 to 6.67E-07) [92]. The same research group 
conducted functional validation studies and found that one SNP in particular 
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(rs11849538) created an estrogen response element (ERE). This finding is significant 
because the ERE demonstrated estrogen receptor binding and increased estrogen 
induction of the TCL1A gene for the variant genotype. These SNPs were also found to 
regulate the expression of cytokines and cytokine receptors in an estrogen-dependent 
manner [93]. These findings link not only inflammation pathways but also estrogen 
signaling to AI-arthralgia. 
1.9 Pharmacogenetics of aromatase inhibitors 
Cytochrome P450 (CYP) enzymes are known to be important to the metabolism of 
endogenous as well as xenobiotic compounds. Certain CYP enzymes, including the 
aromatase CYP19A1, have a limited spectrum of endogenous substrates such as 
androgen. However, other members of the CYP family of enzymes, including those in the 
CYP2 and 3 families are involved in the metabolism of xenobiotics. We know CYP3A4 
and CYP2A6 have been shown to be responsible for metabolizing the currently available 
AIs. Although all patients on AIs take the same daily dose of each of their prescribed 
drugs (2.5mg for letrozole, 1mg for anastrozole, and 25mg for exemestane), there is 
significant interpatient variability in circulating drug concentration [94-99]. A study that 
examined the drug plasma levels of patients on letrozole found that there was more than a 
12-fold variation in drug concentration when corrected for time of the patient’s last dose 
[99].  Similarly, there is a greater than 10-fold variability in plasma concentration of 
anastrozole and exemestane [97]. Thus it is likely variation in the expression and function 
of CYP3A4 or CYP2A6 likely impact attained AI levels, and thereby increase the risk of 
AI-induced arthralgia. Interestingly, switching from one aromatase inhibitor to another in 
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some cases seem to resolve AI arthralgia. One study of patients on anastrozole with AI 
arthralgia demonstrated that 71.5% of patients who switched to letrozole were able to 
tolerate therapy on the second AI [100]. This establishes that patients may experience AI 
arthralgia with one AI, but not another, indicating that inter-patient differences in 
metabolism may play a role, since as noted previously, all of the current AIs are potent 
inhibitors of their target, CYP19A1. Therefore, some of the variation in attained AI levels 
may relate to pharmacogenetic variation [94-97]. 
1.9.1 Letrozole pharmacogenetics 
Letrozole is metabolized to its pharmacologically inactive secondary metabolite, carbinol 
or 4,4-methanol-bisbenzonitrile, by the enzyme CYP2A6 [94, 95].  CYP2A6 is a highly 
polymorphic enzyme, however, most SNPs that have been detected are extremely rare, 
thus unlikely to account for the commonly observed arthralgia during letrozole use. 
However, there are several relatively commonly occurring genetic variations in CYP2A6. 
Such variations include CYP2A6*2, a SNP that results in less than 40% activity, 
CYP2A6*4, a deletion of the gene resulting in no activity, CYP2A6*9, a SNP that results 
in 40-50% activity, and CYP2A6*12, a translocation which results in 40-50% activity 
[101-103]. Letrozole plasma levels were significantly linked to whether a patient was a 
normal, intermediate, or slow metabolizer of letrozole in relation to their CYP2A6 
genotype. Intermediate and slow metabolizers of CYP2A6 consistently had the highest 
levels of letrozole [99]. 
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1.9.2 Anastrozole pharmacogenetics 
Anastrozole is predominantly oxidized in the liver to hydroxyanastrozole by CYP3A4 
and CYP3A5 [96, 97]. For anastrozole, previous studies have shown a range of plasma 
concentration levels of approximately 10ng/ml to 120ng/ml [97]. CYP3A4*22 is a 
relatively recently identified SNP associated with low CYP3A4 activity [104]. For 
CYP3A5, 80% of Caucasians are homozygous for the complete loss of function allele 
CYP3A5*3 [105]. Accordingly, a subset of patients would be predicted to more rapidly 
metabolize drugs such as anastrozole. Note that Phase II enzymes are also involved in the 
further conversion of hydroxyanastrozole to its glucuronide form through the action of 
UGT1A4 and, less commonly, by UGT2B7 and UGT1A3 [97].  
1.9.3 Exemestane pharmacogenetics 
Exemestane is metabolized by two main pathways – it is reduced to its biologically active 
metabolite, 17-hydroexemestane by CYP4A11, CYP1A1, and CYP1A2, and it is 
oxidized to 6-hydroxymethylexemestane by CYP3A4, CYP3A5, CYP2C8 [96].  17-
hydroexemestane is further metabolized by glucuronidation to exemestane-17-O-
glucuronide predominantly by UGT2B17. In vitro studies have shown that an entire gene 
deletion polymorphism of UGT2B17 decreases 17-hydroexemestane glucuronidation 
processes, affecting both metabolism and excretion of the active metabolite [106]. A 
recent paper validated this in humans by demonstrating that a UGT2B17 gene deletion 
polymorphism significantly alters 17-hydroexemestane pharmacokinetic profile [107]. 
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1.10  Vitamin D deficiency in AI-arthralgia 
Vitamin D also appears to play a role in the development of AI-induced arthralgia. 
Vitamin D deficiency and insufficiency are common in post-menopausal women 
initiating adjuvant AI. Several studies have demonstrated that patients who have 
insufficient or deficient levels of vitamin D are more likely to experience arthralgia 
during AI therapy. One study found that patients on AIs with musculoskeletal symptoms 
were more likely to have deficient vitamin D baseline levels when compared to 
asymptomatic patients [108]. Another study found that vitamin D levels were closely 
related to the intensity of the arthralgia, with the most severely affected patients having 
the lowest vitamin D levels [109]. A double-blind placebo-controlled randomized was 
performed with 60 women who were taking anastrozole to establish whether vitamin D 
supplementation could improve the symptoms AI-induced arthralgia. The study found 
that weekly high dose vitamin D significantly improved AI-induced arthralgia [110]. Like 
estrogen, vitamin D has been linked with inflammation signaling pathways, which 
suggests a potential mechanistic role of vitamin D in AI-induced arthralgia [111]. 
However, more research is needed to more fully clarify how vitamin D related factors 
interact with AIs to in terms of joint pain. 
1.10.1 The role of CYP27B1 in vitamin D metabolism 
CYP27B1 encodes 1-α-hydroxylase that catalyzes the hydroxylation of 25(OH)D or 
calcidiol to the bioactive form 1,25(OH)2D or calcitriol. Estrogen is known to increase 
the activity of 1-α-hydroxylase, thereby increasing the conversion of calcidiol to calcitriol 
[72]. Hormone replacement therapy in postmenopausal women has been found to 
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increase circulating levels of calcitriol and is known to support musculoskeletal health 
[112].  An AI-induced decrease in estrogen levels may result in reduced activation of 1-α 
hydroxylase and therefore a reduction in circulating calcitriol levels. Therefore it is 
possible that decreased calcitriol may be contributing to AI arthralgia. 
The potential role of calcitriol in AI arthralgia is supported in a study that identified two 
SNPs in CYP27B1 (rs4646536 and rs10877012) which were associated with AI arthralgia 
and one SNP in CYP27B1 associated with discontinuation of therapy (rs4646536) [79]. 
Interestingly, in this same study, the authors reported an interaction between CYP27B1 
and CYP17A1. Patients who carried risk alleles for both genes had the worst clinical 
response, with the greatest degree of increased arthralgia at 3 months and 1 year of 
follow-up on AIs [79].  
1.10.2 Vitamin D receptor (VDR) 
The vitamin D receptor (VDR) or calcitriol receptor, encoded by the VDR gene, binds to 
calcitriol and mediates its biological activity. VDR is widely expressed in the human 
body and is responsible for regulating the gene expression of a variety of genes involved 
in inflammation, mineral homeostasis, and skeletal health, as well as renal and 
cardiovascular protection [113]. Estrogen is known to increase the activity of vitamin D 
receptor [72]. One SNP in VDR (rs11568820) has been shown to be significantly 
associated with AI arthralgia [79]. The SNP rs11568820 is located in a cdx-2-binding site 
of the VDR promoter. In vitro studies have shown that the presence of this SNP effect 
VDR transcriptional activity and thereby modulate gene expression levels, and of 
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potential functional relevance to AI arthralgia [114]. This Cdx-2 SNP has also been 
previously associated with an increased risk of cancer, particularly ovarian cancer [115]. 
1.11  Specific Aims and Hypotheses 
1.11.1 Specific Aim 1 
Document and quantify adverse drug reactions in patients with ER-positive breast 
cancer on AIs. Based on the allele frequency of the genetic variants to be examined, we 
recruited 200 patients from the London Regional Cancer Program. Clinical variables and 
adverse drug reaction history were recorded.  
Inclusion criteria for enrollment into the study included: 
1) Postmenopausal women with a diagnosis of stage I to stage III estrogen-receptor 
positive breast cancer. 
2) Patients who had completed their initial treatment of surgery, radiation therapy, 
IV chemotherapy regimens or tamoxifen therapy. 
3) Patients who had been prescribed aromatase inhibitor treatment (letrozole, 
anastrozole, exemestane) but had not yet started their medication. 
Exclusion criteria for enrollment into the study included: 
1) Patients who were unable to understand written or spoken English. 
2) Patients who had a psychiatric history or disability that could affect their ability to 
give informed consent. 
Patients recommended for initiation of AI therapy were identified by their treating 
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oncologist and were approached by our research team at their clinic appointments.  Once 
informed consent was obtained, the patients were asked to complete two validated 
questionnaires regarding musculoskeletal side effects. The questionnaires were 
administered to patients on three separate occasions; prior to AI therapy initiation, 
approximately 6 weeks post-initiation and 6 months post-initiation.  The administration 
of questionnaires coincided with the patient's clinic visits to avoid additional 
appointments for the patients. An overview of the study is shown in Figure 1.5.  
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Figure 1.5 Overview of study design 
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The first questionnaire was the Australian/Canadian Osteoarthritis Hand Index 
(AUSCAN), version 3.1, which is a 15-item questionnaire that assesses pain, stiffness, 
and physical functioning of the hands. The AUSCAN is a reliable measure of clinical 
outcomes and has validated age and gender-specific normative values [98, 116]. The 
questionnaire contains three subscales (pain, stiffness, and physical functioning); each is 
scored as the sum of the items on the subscale. An example of the AUSCAN 
questionnaire is attached as Appendix C. The second questionnaire that was administered 
was the Western Ontario and McMaster Osteoarthritis Index (WOMAC), version 3.1. 
This clinical tool assesses pain, stiffness, and physical functioning in the lower 
extremities, knees, and hips. The questionnaire has 24 items and validated age- and 
gender-specific normative values are available [117]. The WOMAC consists of three 
subscales (pain, stiffness, and physical functioning), each scored as the sum of the items 
on that subscale. An example of the WOMAC questionnaire is attached as Appendix D. 
An important element of this aim was to evaluate whether there are changes in the 
occurrence of adverse drug reactions over time. In order to test whether AI-induced 
arthralgia increase over time, I administered the AUSCAN and WOMAC questionnaires 
and measured changes over 6 months. AI-induced arthralgia symptoms have been 
reported to typically appear in the first 6 months of treatment.  The first symptoms tend to 
appear within the first month of drug initiation, and intensifying in the second and third 
months of drug use [71]. Because AI-induced arthralgia have not been known to emerge 
or be reported for the first time after the 6 month point, we chose our patient follow-up 
times to be 6 weeks and 6 months. Oncologists at the LRCP typically see patients in 
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clinic at 6 weeks and 6 months following initiation of therapy, and I collected blood 
samples and administered two questionnaires at patients’ regular appointments. 
1.11.2 Specific Aim 2 
Measure drug levels of AIs and vitamin D levels in breast cancer patients to 
determine the range of AI levels in response to standard doses. By measuring drug 
concentration levels of patients on AIs, we were able to determine whether some patients 
were outside the therapeutic range, either sub-therapeutic which may affect efficacy or a 
higher than normal drug concentration level which may cause toxicity. Blood samples 
were be obtained for drug level analysis by liquid chromatography/mass spectrometry 
and vitamin D level analysis at 6 weeks and 6 months post-initiation of therapy. Drug 
concentration level analysis of the aromatase inhibitors was achieved by using liquid 
chromatography/mass spectrometry, as described in Chapter 4. 
1.11.3 Specific Aim 3 
Determine the genotype of relevant genes in the metabolic pathway of AIs including 
CYP3A4, CYP3A5, and CYP2A6. Determine the genotype of other potential 
arthralgia biomarkers, including the estrogen synthesis pathway (ESR1, CYP19A1), 
the inflammation pathway (OPG, RANKL, TLC1A), and the vitamin D pathway 
(VDR and CYP27B1). Blood samples were obtained for genotyping by TaqMan SNP 
assays. Statistical modeling on our patient cohort was used to determine important 
genetic predictors of AI efficacy and adverse drug reaction risk.  
A thorough review of the current literature has revealed which genes are known to 
contribute to the metabolism of AIs. The gene product of CYP2A6 metabolizes letrozole 
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to its pharmacologically inactive secondary metabolite called carbinol or 4,4-methanol-
bisbenzonitrile [94, 95]. There are more than 50 different types of variation in CYP2A6, 
however most SNPs that have been detected are extremely rare, and may not affect the 
activity of CYP2A6. Therefore, I genotyped patients using the 4 most common star-alleles 
found within our target population. These included CYP2A6*2, a SNP that results in less 
than 40% activity, CYP2A6*4, a deletion of the gene resulting in no activity, CYP2A6*9, 
a SNP that results in 40-50% activity, and CYP2A6*12, a translocation which results in 
40-50% activity [101-103]. As described in Chapters 2, 5, and 6, SNPs from estrogen 
synthesis pathway (ESR1, CYP17A1, CYP19A1), the inflammation pathway (OPG, 
RANKL, TLC1A), and the vitamin D pathway (VDR and CYP27B1) were chosen based on 
previous literature in this field. 
1.11.4 Hypotheses 
The variability within genes and pharmacokinetics of the AIs in patients with breast 
cancer explains much of the differences in efficacy and adverse drug reactions between 
individuals. We hypothesized that polymorphisms in CYP2A6 and CYP3A4/5 are 
associated with altered plasma drug levels and adverse drug reactions. Variation in other 
arthralgia biomarker genes (ESR1, CYP19A1, OPG, TLC1A, RANKL, VDR, and 
CYP27B1) may explain arthralgia through additional pathways. Understanding the 
variability can also support the prediction of optimal drug levels, thereby improving 
efficacy and safety of outcomes in breast cancer patients. 
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1.12  Outline of thesis 
The analyses in this thesis have been done on a population of 200 postmenopausal 
women with breast cancer who were initiated on two different aromatase inhibitors, 
letrozole and anastrozole. We did not have any patients enrolled on exemestane at our 
site at the London Regional Cancer Program. Chapter 2 focuses on a sub-analysis of the 
126 patients that were on letrozole.  We selected these patients for a sub-analysis of the 
total group to measure letrozole drug levels and genotypes related specifically to letrozole 
metabolism. Because there were only 70 patients on anastrozole and no patients on 
exemestane, we did not measure drug levels in these patients. Chapters 3 and 4 focus on 
the full population of patients on AIs with the patients on letrozole and anastrozole 
grouped together. Chapter 3 examines SNPs in the estrogen and inflammation pathways 
and their association with AI induced arthralgia. Chapter 4 investigates the effect of 
vitamin D on AI induced arthralgia, including both vitamin D levels and SNPs within the 
vitamin D pathway. 
1.13  Conclusion 
Breast cancer is both the most common cancer and one of the leading causes of death in 
women. Approximately 80% of breast cancer in postmenopausal women is ER-positive, 
indicating that these tumours respond to estrogen, which promotes cancer cell 
proliferation. AIs are the most commonly used first-line endocrine treatment for 
postmenopausal women with ER-positive breast cancer, but AI activity varies widely 
among patients. AIs, including letrozole, anastrozole, and exemestane, have been found 
to deplete estrogen levels, reducing tumour growth and limiting disease progression and 
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recurrence. Significant ADRs are associated with AIs, the most common being arthralgia. 
Currently, the therapeutic response and occurrence of adverse effects with AIs for ER-
positive breast cancers is largely unpredictable. Candidate genes and molecular 
biomarkers associated with AI arthralgia offer valuable insight into the complex 
mechanism of the adverse drug reaction. Additional research is needed to replicate and 
validate candidate genes and biomarkers to develop utility in a clinical setting to prevent 
the development of AI arthralgia. Understanding endocrine-based treatments and their 
associated ADRs will help clinicians better manage AI therapy and deliver better care to 
patients with breast cancer. 
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WITH CYP2A6 VARIATION BUT NOT WITH 
ARTHRALGIA IN PATIENTS WITH BREAST CANCER 
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2.1 Introduction 
Aromatase inhibitors (AIs) are the most commonly used first-line endocrine treatment for 
postmenopausal women with estrogen receptor-positive (ER-positive) breast cancer [1]. 
Several adverse drug reactions (ADRs) are associated with AIs with the most common 
being arthralgia; specifically, bilateral arthritic joint pain affecting the hands, elbows, 
shoulders, hips, and knees [2]. AI-induced arthralgia affects up to 50% of patients and 
20-30% of patients discontinue the medication due to intolerable symptoms [3]. Although 
the etiology is currently unknown, several underlying mechanisms have been proposed, 
including AI metabolism and pharmacogenetic factors [4].  
Letrozole is one of three third-generation selective AIs and is prescribed as a 
standard dose of 2.5mg daily for five years. The terminal half-life of letrozole is 48 hours, 
and steady-state plasma concentration is reached in two to six weeks [5]. Letrozole is 
metabolized primarily by cytochrome P450 2A6 (CYP2A6), an enzyme encoded by the 
CYP2A6 gene, which is expressed mainly in the liver [6-8]. There are over 50 types of 
CYP2A6 genetic alterations which effect its’ enzymatic activity. However, many of these 
variants are rare, with minor allele frequencies of less than one percent. CYP2A6*1 
represents the wild-type, or reference allele, and indicates normal CYP2A6 function. The 
variant alleles most commonly found in Caucasian populations are CYP2A6*2, 
CYP2A6*4, CYP2A6*9, and CYP2A6*12 [9]. CYP2A6*2 is a single nucleotide 
polymorphism (SNP) that results in less than 40% enzyme activity. CYP2A6*4 represents 
a deletion of the gene resulting in no activity [10]. CYP2A6*9 is a SNP within the TATA 
box of the CYP2A6 promoter region that results in a 50-60% reduction in activity [11]. 
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CYP2A6*12 is a translocation which is caused by a crossover between the CYP2A6 and 
CYP2A7 genes, resulting in a hybrid allele, and 40-50% activity [12]. 
Despite being prescribed as a standard dose, plasma concentrations of letrozole vary 
greatly, ranging from 25ng/mL to 350ng/mL [7]. Several clinical factors have been found 
to be associated with letrozole plasma concentration. Circulating concentrations of 
letrozole are found to be negatively correlated with BMI and positively correlated with 
age [7]. Furthermore, variation in CYP2A6 explains a large degree of the variability in 
steady-state letrozole concentrations in patients with breast cancer [7] and healthy 
postmenopausal women [13].  
Though AI-induced arthralgia is widely recognized as the most common adverse 
reaction for breast cancer patients taking letrozole, there is little consensus on how best to 
measure these symptoms. A study by Swenson et al. compared the responsiveness of six 
validated self-report questionnaires of musculoskeletal symptoms and two performance-
based tests of physical function during treatment with AIs [14]. They found that the 
instruments with the greatest sensitivity to changes over the first six months of AI use 
were the Australian/Canadian Osteoarthritis hand index (AUSCAN) and the Western 
Ontario and McMaster Osteoarthritis Index (WOMAC) [15].  Importantly, the physical 
function subscales of the AUSCAN and WOMAC were the most sensitive to change and 
able to effectively translate the measures of pain and stiffness to the impact on a patient’s 
life. 
While studies measuring letrozole concentration have established an association between 
genotype and drug concentration, there is a lack of prospective studies that specifically 
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examined the effect of plasma concentration and CYP2A6 genotype on the development 
of letrozole-related arthralgia. We hypothesized that genetic polymorphisms in CYP2A6 
were associated with altered letrozole plasma levels and arthralgia. In this study, we 
prospectively examined the association of WOMAC and AUSCAN scores with 
circulating levels of letrozole and CYP2A6 genotypes in postmenopausal women initiated 
on letrozole therapy. 
2.2 Materials and Methods  
2.2.1 Study population 
Postmenopausal breast cancer patients (n = 126) diagnosed with stages I-III ER-positive 
breast cancer initiating letrozole therapy were enrolled at the London Regional Cancer 
Program in London Ontario between April 2015 – December 2017. All study participants 
provided written informed consent. This study was approved by the Research Ethics 
Board at the University of Western Ontario. 
2.2.2 Sample collection and storage 
Blood samples were obtained from each patient at three time points: prior to letrozole 
therapy initiation, approximately two months post-initiation, and six months post-
initiation on 2.5mg of letrozole. The date and time of blood collection and last letrozole 
dose were recorded and used to calculate the time (in hours) since the last dose. Plasma 
was isolated from venous blood and stored at -80°C until analysis.  
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2.2.3 Letrozole measurement 
Steady-state plasma letrozole concentration was measured by liquid chromatography-
mass spectrometry (LC-MS/MS) using methods as described previously [16]. Letrozole 
and the internal standard, letrozole-D4, were obtained from Toronto Research Chemicals 
(Toronto, Ontario, Canada). Plasma samples (150 μL) were prepared with 10 μL of 
internal standard and underwent solid phase extraction in BondElut C18 96-well plates 
(Agilent Technologies, Santa Clara, California, USA). Upon injection into the liquid 
chromatograph (Agilent 1200) the molecules were separated on a ZORBAX Eclipse 
XDB-C18 column using a gradient elution with acetonitrile in 0.1% acetic acid. Standard 
curves and quality control samples were prepared in drug-free plasma. The Thermo TSQ 
Vantage mass spectrometer with heated electrospray ionization source was set in positive 
mode for detection of letrozole and letrozole-D4 with transitions of 286.1→ 217 m/z and 
290.1→ 221 m/z respectively. 
2.2.4 Genotyping 
DNA was extracted from whole EDTA blood using either the MagNA Pure Compact 
instrument (Roche, Laval, Quebec, Canada) or the MagMaxTM Express instrument 
(Thermo Fisher Scientific, Waltham, Massachusetts, United States). DNA samples were 
stored at -20°C until analysis. The following TaqMan® allelic discrimination assays 
(Applied Biosystems, Carlsbad, CA) were used for genotyping: CYP2A6*2 (rs1801272, 
assay ID: C__27861808_60), CYP2A6*9 (rs28399433, assay ID: C__30634332_10), 
CYP2A6*12 (rs4803380, assay ID: C__32350075_20). A TaqMan® gene copy number 
assay (Applied Biosystems, Carlsbad, CA) was utilized to detect gene deletion (*4) and 
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duplication (assay ID: Hs07545274_cn). Hardy-Weinberg equilibrium was assessed for 
all genotypes using the chi-square goodness-of-fit test. Individuals with one copy of the 
CYP2A6*9 decreased-function allele were categorized as intermediate metabolizers; 
those with two copies of the CYP2A6*9 allele or one or two copies of loss-of-function 
alleles (CYP2A6*2, *4, and *12) were categorized as slow metabolizers as described 
previously [7]. 
2.2.5 Clinical data collection 
Patient demographics including age, height, weight, ethnicity, and medication history 
were documented at the time of the first blood draw, and the letrozole start date was 
recorded. Cancer stage, as well as ER, progesterone receptor (PR), and human epidermal 
growth factor 2 (HER2) status were collected from the patients’ medical chart.  
2.2.6 Instruments 
Patients were asked to complete two musculoskeletal questionnaires, the AUSCAN 
version 3.1 and the WOMAC version 3.1, which were previously validated as sensitive 
measures for AI-induced arthralgia [14]. The AUSCAN is a 15-item questionnaire 
assessing pain, stiffness, and physical function in the upper body extremities, with 
possible scores ranging from 0-20 for pain, 0-4 for stiffness, and 0-36 for physical 
function [15]. The WOMAC is a 24-item questionnaire that assesses pain, stiffness, and 
physical function in the lower extremities, with possible scores ranging from 0-20 for 
pain, 0-8 for stiffness, and 0-68 for physical function [15]. For both instruments and their 
subscales, higher scores represent worse symptoms. Both questionnaires were completed 
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by participants at the time of each of the three blood draws: prior to letrozole therapy 
initiation, at two months post-initiation, and six months post-initiation.  
2.2.7 Statistical analysis 
All statistical analyses were performed using R (version 3.31) [17] and GraphPad Prism 
(version 6.0, San Diego, CA) statistical software. All tests were two-sided and were 
considered statistically significant at P ≤ 0.05. A student’s t-test was performed to 
determine whether letrozole plasma concentration differed between patients who were 
normal and reduced metabolizing patients. A linear mixed effect model was used to 
assess the association between letrozole plasma concentration, genotype, and time since 
last dose while adjusting for BMI and age. The same linear mixed effects model was used 
for modelling AUSCAN and WOMAC scores repeatedly measured over time. We 
compared adjusted mean questionnaire scores at each visit to estimate the effect of time 
by visit while adjusting for age, BMI, and genotype. Multiple linear regression analyses 
were performed to assess the effects estimate of age, BMI, and letrozole concentration on 
the outcome of change in AUSCAN and WOMAC scores. P values for these estimates 
were adjusted for multiple testing using the Holm-Bonferroni method. 
2.3 Results 
2.3.1 Patient demographics and medication history 
We analyzed clinical variables and letrozole concentration data from 126 patients with 
participant characteristics summarized in Table 2.1. Of these, 116 (92.1%) completed at 
least two months of treatment and returned for follow-up visit 1, and 83 (65.9%) 
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completed the six-month follow-up 2 visit (Figure 2.1). The majority of patients were 
Caucasian (92.4%). Patients were not on any CYP2A6 inhibiting drugs (methoxsalen, 
selegiline, tranylcypromine, ketoconazole) [18]. All patients were initiated on the 
standard dose of 2.5mg of letrozole, with no adjustments in the dose.  
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Table 2.1 Patient demographics (n = 126) 
Patient characteristic   
Age (Median (Min, Max)) 65.5 (31, 88) 
BMI (Median (Min, Max)) 29.3 (20.1, 52.6)  
Race/Ethnicity  (N (%)) 
    Caucasian 118 (92.4%) 
   Asian 2 (1.6%) 
   Other 6 (4.8%) 
ER status (N (%)) 
    Positive 126 (100%) 
   Negative 0 
PR status (N (%)) 
    Positive 106 (84.1%) 
   Negative 20 (15.9%) 
HER2 status (N (%)) 
    Positive 16 (12.6%) 
   Negative 110 (87.3%) 
Stage of cancer (N (%)) 
    I (A/B) 38 (30.2%) 
   II (A/B) 68 (54.0%) 
   III (A/B/C) 20 (15.8%) 
   IV 0 
BMI body mass index; ER estrogen receptor; PR progesterone receptor; HER2 human 
epidermal growth factor receptor 2 
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Figure 2.1 Flow chart for patient inclusion 
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2.3.2 Letrozole plasma concentrations 
Plasma samples from the first and second follow-up visits were available from 105 and 
66 enrolled patients, respectively. We observed a 16-fold variation in letrozole 
concentration level, with a median of 90.1 ng/mL and a range of 15.1 – 247.4 ng/mL. 
Time since last dose in hours was calculated for each follow-up visit. All patients had 
taken their daily dose of letrozole within the past 24 hours of blood draw and patients 
who self-reported non-compliance with their medication (n = 2) were excluded in the 
final analysis.  The time since last dose was statistically significant (P = 0.01) when age, 
BMI, and genotype were corrected for, however the effect estimate of time since last dose 
was minimal (effect estimate = -0.84 [95%CI, -1.48 to -0.18]), meaning that for each 
hour of time, letrozole concentration decreased 0.84 ng/mL. This indicates that time since 
last dose has very little impact on letrozole concentration and is consistent with the 
known long half-life (48 hours) of letrozole, demonstrating that patients were at a steady-
state concentration. 
2.3.3 Effect of genotype and clinical variables on letrozole 
concentration 
CYP2A6 genotype information is summarized in Table 2.2. Patients were classified as 
normal (n = 92; *1/*1), intermediate (n = 23; *1/*9), or slow (n = 11; *9/*9, *1/*2, 
*1/*4, *1/*12) metabolizers of letrozole based on their genotype as previously 
characterized [7]. Accordingly, 34 (27.0%) of patients were determined to have CYP2A6 
reduced-function genotypes. We did not detect any gene duplication of CYP2A6 in this 
patient population. Normal metabolizers had significantly lower plasma letrozole 
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concentrations (median, 82.53 (min, max; 15.10, 179.70) ng/mL) than reduced 
metabolizers (median, 116.80 (min, max; 75.56, 247.40) ng/mL) (P < 0.0001) (Figure 
2.2). Letrozole concentration was significantly associated with both BMI (effect estimate 
= -1.92, [95% CI, -2.91 to -0.92], P = 0.0001) and age (effect estimate = 0.96 [95% CI, 
0.04 to 1.88, P = 0.04) (Figure 2.3). When taking repeated visits into account, as well as 
adjusting for age, BMI, and time since last dose, the reduced metabolizer genotype 
remained significantly associated with letrozole concentration; the letrozole concentration 
level for those with reduced metabolizer genotypes was 36.55 ng/mL higher on average 
than that for those with normal metabolizer genotypes ([95% CI, 22.63 to 50.47], P < 
0.0001). 
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Table 2.2 SNP information and genotyping quality control (n = 126) 
Gene 
Common  
allele 
name rs ID 
Allelic 
change 
Call 
rate 
MAF  
in this 
cohort 
HWE 
P 
value 
CYP2A6 *2 rs1801272 1799T>A 1.0 0.03 0.01 
CYP2A6 *4 N/A gene deletion 1.0 0.004 0.89 
CYP2A6 *9 rs28399433 -48T>G 1.0 0.09 0.96 
CYP2A6 *12 rs4803380 translocation 1.0 0.008 0.92 
SNP single nucleotide polymorphism; MAF minor allele frequency; HWE Hardy–
Weinberg equilibrium 
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Figure 2.2 Plasma letrozole concentration significantly associated with CYP2A6 
genetic variation 
Statistical test: student’s t-test 
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Figure 2.3 Influence of age and BMI on letrozole concentration 
Letrozole concentration was positively associated with (a) age (R2 = 0.040, P = 0.043) 
and inversely associated with (b) BMI (R2 = 0.1181, P = 0.0003). Solid line linear 
regression line; dotted lines 95% confidence intervals. Statistical test: Linear mixed 
effects model. 
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2.3.4 Measurement of arthralgia symptoms 
For patients who completed follow-up visit 1, 64 of 116 (55.2%) experienced increases in 
their AUSCAN score, and 62 of 116 (53.4%) experienced increases in their WOMAC 
score compared to baseline. For patients who completed a second follow-up visit, 44 of 
the 83 (53.0%) experienced score increases on the AUSCAN, and 42 of the 83 (50.6%) 
experienced score increases on the WOMAC compared to baseline. Mean AUSCAN and 
WOMAC scores at each follow-up visit and the effect estimate of time by visit (adjusted 
by age, BMI, and genotype) using a mixed effects regression model are summarized in 
Table 2.3. We observed positive effect estimate of time on mean scores; mean scores 
increased from baseline to the first and second follow-up visits for the WOMAC for each 
measure (pain, stiffness, physical functioning and total score). We observed positive 
effect estimate of time between mean scores from baseline to the second follow-up for 
each AUSCAN measure (pain, stiffness, physical functioning and total score) and for 
pain and total score for the first follow-up visit. All of the visit effects were positive for 
each WOMAC and AUSCAN measure comparing visits 1 and 2 to the baseline, 
indicating that pain, stiffness, and difficulty with physical function increased over the 
follow-up periods. Furthermore, 42 of 126 patients (33.3%) discontinued their letrozole 
due to intolerable arthralgia. The mean time to discontinuation for patients who stopped 
using the medication was 140 days (SD = 108 days) with a median time to 
discontinuation of 92 days. Patients who discontinued letrozole before the first or second 
follow-up were excluded from the analysis and did not provide follow-up samples or 
questionnaires. Specifically, eight patients discontinued letrozole due to arthralgia 
between baseline and follow-up visit 1. A sub-analysis of the patients who discontinued 
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between follow-up visit 1 and follow-up visit 2 due to arthralgia (n = 26) and the patients 
who continued on letrozole for at least 6 months and completed their second follow-up 
visit (n = 83) revealed that the group that discontinued had a significantly higher change 
in AUSCAN scores at follow-up visit 1 (P = 0.027). Letrozole level, age, BMI, and 
WOMAC score were not significantly different between the two groups.  
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Table 2.3 Adjust mean questionnaire scores at three time points 
  
Baseline  
(n = 126) 
  
Follow-up visit 1  
(n = 116) 
  
Mean 
 
Mean Estimate 95% CI Sig. 
AUSCAN 
           Pain  2.34 
 
3.31 0.97 0.29 to 1.66 * 
     Stiffness 0.72 
 
0.88 0.16 -0.02 to 0.34 * 
     Physical functioning 4.55 
 
5.15 0.60 -0.39 to 1.58 * 
     Total score 7.61 
 
9.36 1.75 0.12 to 3.37 * 
WOMAC 
           Pain  2.95 
 
3.69 0.74 0.13 to 1.36 * 
     Stiffness 1.66 
 
2.03 0.37 0.06 to 0.68 * 
     Physical functioning 9.29 
 
11.66 2.37 0.73 to 4.01 * 
     Total score 13.90   17.4 3.50 1.18 to 5.81 * 
 
 
(Table 2.3 continued) 
  
Follow-up visit 2  
(n = 82) 
  Mean  Estimate 95% CI Sig. 
AUSCAN 
         Pain  4.16 1.82 1.02 to 2.62 * 
     Stiffness 1.12 0.40 0.19 to 0.61 * 
     Physical functioning 6.88 2.33  1.19 to 3.48 * 
     Total score 12.24 4.62 2.73 to 6.52 * 
WOMAC 
         Pain  4.04 1.09 0.38 to 1.81 * 
     Stiffness 2.22 0.56 0.20 to 0.92 * 
     Physical functioning 12.94 3.64 1.73 to 5.56 * 
     Total score 19.20 5.32 2.61 to 8.03 * 
AUSCAN Australian/Canadian Osteoarthritis Hand Index; WOMAC Western Ontario and 
McMaster Osteoarthritis Index; CI confidence interval Sig. Significant. Statistical test: 
mixed effects regression model. All scores and effect estimates are corrected for age, 
BMI, and genotype. Significance indicates that the 95% confidence interval for the effect 
estimate does not cross zero. 
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2.3.5 Letrozole concentration does not affect WOMAC and 
AUSCAN scores 
Simple linear regression analyses showed that a change in AUSCAN scores was not 
significantly associated with steady-state letrozole concentration at follow-up visit 1 (n = 
105) or follow-up visit 2 (n = 66). Changes in WOMAC scores at follow-up visit 1 (n = 
105) and follow-up visit 2 (n = 66) suggested a very weak negative association with 
letrozole concentration. However, when P values were corrected for multiple testing 
using the Holm-Bonferroni method, the change in WOMAC score was not found to be 
associated with letrozole concentration, age or BMI (Table 2.4) 
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Table 2.4 Influence of clinical factors on change in WOMAC and AUSCAN scores 
Outcome 
Predictor 
variable 
Effect 
estimate 95% CI P value  
Adjusted  
P value 
Change in WOMAC  Age -0.132  -0.260 to -0.003 0.045 0.135 
(Follow-up visit 1) BMI 0.077  -0.030 to 0.184 0.156 0.282 
 
[Letrozole] -0.445  -1.041 to 0.151 0.141 0.282 
Change in WOMAC  Age -0.100  -0.203 to 0.005 0.062 0.124 
(Follow-up visit 2) BMI 0.083  -0.020 to 0.187 0.115 0.124 
 
[Letrozole] -0.857  -1.608 to -0.105 0.026 0.078 
Change in AUSCAN Age -0.079  -0.258 to 0.100 0.383 1.000 
(Follow-up visit 1) BMI 0.024  -0.124 to 0.172 0.744 1.000 
 
[Letrozole] -0.331  -1.159 to 0.498 0.43 1.000 
Change in AUSCAN Age -0.118  -0.286 to 0.049 0.162 0.324 
(Follow-up visit 2) BMI -0.080  -0.229 to 0.068 0.283 0.324 
  [Letrozole] -0.883  -1.964 to 0.199 0.108 0.324 
AUSCAN Australian/Canadian Osteoarthritis Hand Index; WOMAC Western Ontario and 
McMaster Osteoarthritis Index; CI confidence interval; Statistic test: Linear regression. P 
value was adjusted using the Holm–Bonferroni method 
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2.3.6 CYP2A6 genotype does not predict arthralgia symptoms 
There was no difference in combined pain scores between reduced metabolizers relative 
to those in normal metabolizers at the first follow-up visit (n = 116, P = 0.30) and second 
follow-up visit (n = 83, P = 0.76) time points (Figure 2.4) using two-tailed unpaired t-
tests. A linear random intercept model was utilized to account for repeated measures and 
adjust for age and BMI, failed to detect an association between increased WOMAC and 
AUSCAN scores for follow-up visit 1 (effect estimate = -0.39 [95% CI, -5.70 to 4.92], P 
= 0.886) or follow-up visit 2 (effect estimate = -0.87 [95% CI, -7.04 to 5.29], P = 0.78). 
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Figure 2.4 No association was found between change in pain score and CYP2A6 
genotype 
No association was found between change in pain score and CYP2A6 activity the first 
follow-up visit (n = 116, R2 = 0.009, P = 0.2981) or second follow-up visit (n = 83, R2 = 
0.001, P = 0.7530). Statistical test: linear random intercept model was utilized to account 
for repeated measures and adjust for age and BMI 
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2.4 Discussion 
This is the first study to use the AUSCAN and WOMAC assessment tools to measure the 
effect of letrozole concentration and CYP2A6 genotype on letrozole-induced arthralgia in 
patients with ER-positive breast cancer. In this prospective cohort of 126 patients, we 
confirmed that there was a significant association between letrozole concentration and 
CYP2A6 genotype. However, changes in AUSCAN and WOMAC scores were not 
associated with letrozole concentration. Furthermore, the CYP2A6 genotype was not 
significantly associated with a change in arthralgia symptoms. Thus, these results suggest 
that systemic letrozole concentrations and CYP2A6 genotype are not clinically 
meaningful predictors of AI-induced arthralgia. 
Thirty-four patients (27%) in this study had a genotype that is associated with 
decreased CYP2A6 function. Patients carrying at least one of the CYP2A6 reduced-
function genotypes (*2, *4, *9, or *12) had significantly higher steady-state letrozole 
concentrations than patients lacking these variations. This finding is consistent with 
previous studies [7, 13]. We observed a 16-fold variation in the plasma concentration of 
letrozole level, which was significantly associated with CYP2A6 genotype, age, and BMI. 
The CYP2A6 genotype accounted for 17% of the explained variability, while BMI and 
age accounted for 12% and 4%, respectively. 
The AUSCAN and WOMAC are validated self-report tools that effectively assess 
pain, stiffness and physical function changes, and can detect early letrozole-induced 
arthralgia symptoms. In this cohort, we found that mean scores on each subscale of the 
AUSCAN and WOMAC increased over the duration of letrozole treatment, indicating 
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worsening pain, stiffness, and physical function. Of note, the most substantial increase in 
AUSCAN and WOMAC scores occurred between baseline and follow-up visit 1, 
indicating arthralgia symptoms do not appear to increase linearly over time. Patients with 
an increase in AUSCAN score at follow-up visit 1 were more likely to be in the group 
that discontinued their medication by follow-up visit 2. However, individual factors such 
as stage of cancer and risk of recurrence may influence patient motivation for continuing 
on therapy despite AI-induced arthralgia. Further research is needed to determine whether 
clinicians could utilize these tools to predict which patients may discontinue letrozole 
therapy due to intolerable arthralgia. Clinicians may be able to better measure arthralgia 
symptoms by asking patients to complete AUSCAN and WOMAC questionnaires at 
regular intervals throughout the course of letrozole therapy, either through paper 
questionnaires or by recording the data in an electronic mobile phone application. These 
measures have been adapted and validated for mobile phone use to electronically capture 
the pain, stiffness, and physical function data, as well as recording date and time of 
assessment [19, 20]. Data can then be sent electronically to their physician where it can 
be stored in their electronic health record and evaluated, better informing clinicians of 
their patients’ response to medication and potential for discontinuation. 
An advantage of our study is that we collected data prospectively, and blood samples 
were taken at the same time as the AUSCAN and WOMAC were administered. The 
AUSCAN and WOMAC request that patients comment on the severity of their most 
recent symptoms from the past 48 hours [15]. Because letrozole has a long half-life [5] 
and time since last dose was recorded, letrozole levels in compliant patients were 
assumed to be in steady state. Our measurements of symptoms and drug levels were 
69 
 
robust, and therefore method inaccuracy is unlikely to explain an absence of an observed 
association. A larger study may confirm our findings with a greater degree of certainty. 
A limitation of this study was the difficulty in collecting plasma samples or 
questionnaires from patients who discontinued their drug between the baseline and 
follow-up visits. Thus, for those patients, it is difficult to determine whether arthralgia 
was associated with letrozole plasma concentration. We were not able to analyze data 
from patients who discontinued letrozole before follow-up visit 1 as letrozole 
concentration, and AUSCAN and WOMAC scores were not collected. However, we did 
perform a sub-group analysis on the patients who discontinued their letrozole between 
follow-up visit 1 and follow-up visit 2. We found that those who discontinued had a 
significantly higher mean change in AUSCAN scores at follow-up visit 1 compared to 
patients who remained on letrozole therapy for the full 6 months. This provides further 
evidence that AUSCAN and WOMAC scores should be investigated as potentially 
predictive clinical assessment tools. 
There are likely other clinical characteristics and genetic factors contributing to 
changes in pain, stiffness, and physical function scores, and the probability of patients 
discontinuing letrozole treatment due to arthralgia. A prospective study of 135 female 
patients with no prior pain who were on aromatase inhibitors investigated a number of 
different clinical, biological, environmental, and genetic risk factors for the development 
of arthralgia [21]. The authors found that patient anxiety may be a predictor of the 
development of AI-induced arthralgia [21]. As we did not measure anxiety, depression, 
or other psychological factors, further investigation is needed to replicate these findings. 
Additional SNPs in estrogen and inflammation pathways have been found to be 
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associated with AI-induced arthralgia in candidate gene and genome-wide analyses [4, 
22]. However, these genetic findings remain to be replicated in prospective studies in 
order to determine if they are reliable predictors of AI-induced arthralgia. 
Overall, this study indicates that CYP2A6 genotype, age, and BMI are predictors of 
letrozole concentration. Although we did not observe an association between letrozole 
levels and arthralgia symptoms, we did find that the AUSCAN and WOMAC instruments 
are very useful measures of AI-induced pain, stiffness, and changes in physical function. 
These measures may be applied in clinical practice to monitor AI adverse effects. They 
could also be used to further investigate AI-induced arthralgia mechanisms as well as 
therapeutic interventions to reduce arthralgia.  
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3 GENETIC AND CLINICAL PREDICTORS OF 
AROMATASE INHIBITOR ARTHRALGIA IN BREAST 
CANCER PATIENTS 
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3.1 Introduction 
Breast cancer is the most common cancer in females worldwide, as well as the leading 
cause of cancer death in women [1]. As many as 80% of breast cancers are estrogen 
receptor (ER)-positive, meaning that the tumour grows in response to estrogen [2]. Anti-
estrogen therapy includes tamoxifen for pre-menopausal women and aggressive tumours. 
Aromatase inhibitors (AIs) are well established as the most effective first-line endocrine 
treatment for postmenopausal women with ER-positive breast cancer and the most 
commonly used treatment in North America [3]. Aromatase inhibitors work through their 
inhibition of the aromatase enzyme, which is encoded by the CYP19A1 gene [4]. 
Aromatase catalyzes the final step in the estrogen production pathway [5]. By inhibiting 
aromatase, these drugs reduce the amount of estrogen to nearly undetectable levels. All 
three aromatase inhibitors, letrozole, anastrozole, and exemestane have nearly identical 
effectiveness in reducing estrogen levels, but also have similar adverse drug reaction 
(ADR) profiles. The clinical impact of AIs varies widely among patients and up to 50% 
of patients experience ADRs, with the most common being arthralgia. These reactions 
adversely impact the quality of life for patients, leading to compromised compliance and 
contribute to early discontinuation [6]. The mechanism of the ADRs is largely unknown. 
A number of different scales and measures have been employed to evaluate the 
intensity of the pain and stiffness that a patient with AI-induced arthralgia experiences, as 
well as the effect on the patient’s quality of life. A prospective, longitudinal study by 
Swenson et al. [7] examined the responsiveness of standardized self-reported measures of 
AI-induced arthralgia, comparing six different questionnaires administered to 122 
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patients assessed at baseline, and at one, three, and six months post-initiation of therapy. 
They concluded that the Australian/Canadian Osteoarthritis Hand Index (AUSCAN), the 
Western Ontario and McMaster Osteoarthritis Index (WOMAC) had the greatest 
sensitivity and responsiveness in detecting and measuring AI-induced arthralgia. 
Previous pharmacogenomic studies have attempted to identify biomarkers that predict 
drug response by investigating the association of ADRs with genetic variation in patients. 
Polymorphisms within genes in the estrogen pathway (CYP19A1, ESR1) and genes 
associated with inflammation (OPG, TCLA1, RANKL) have been shown to be associated 
with AI arthralgia [8]. Although several candidate SNPs have been identified, there are 
no established clinical practice guidelines currently, so a personalized medicine approach 
cannot be implemented within a clinical setting. Replication and validation of these 
biomarkers are an essential next step to advance these discoveries into implementation in 
patient care. We conducted a prospective study of patients treated with AIs and measured 
their arthralgia through the course of their treatment using the validated AUSCAN and 
WOMAC questionnaires. 
3.2 Methods 
3.2.1 Study design and participants 
Female patients (n = 196) who were prescribed AI therapy were recruited from the 
London Regional Cancer Program, London, Ontario, Canada between April 2015 and 
December 2017. All study participants provided written informed consent. The study was 
approved by the Research Ethics Board at the University of Western Ontario. 
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3.2.2 Demographics and medication history 
Demographic information including gender, age, height, weight, and ethnicity of the 
participants was recorded at the patient’s initial clinic visit. The type of AI prescribed, 
dose, date of initiation, and concomitant medication history were also recorded. At each 
follow-up visit, participants were asked whether they were still on AI treatment, and if 
not, the reason they had stopped and the date of their last dose. The cancer stage, as well 
as ER, progesterone receptor (PR), and human epidermal growth factor receptor 2 
(HER2) status were collected from the patients’ medical chart. 
3.2.3 Sample collection and storage 
Blood samples were obtained from each patient at three time points: prior to AI therapy 
initiation, approximately two months’ post-initiation, and six months’ post-initiation on 
2.5mg of letrozole or 1mg of anastrozole. Blood samples were immediately stored at 4°C 
before DNA extraction. 
3.2.4 Arthralgia assessment 
Participants were assessed at three time points: A baseline assessment was completed 
prior to initiation on AI therapy, at approximately two months post initiation and again at 
six months post initiation. The AUSCAN, version 3.1 and the WOMAC, version 3.1 
questionnaires were administered during clinic visits where blood samples were obtained. 
The AUSCAN is a 15-item questionnaire that assesses pain, stiffness, and physical 
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functioning of the hands. The WOMAC is a 24-item questionnaire that evaluates pain, 
stiffness, and physical functioning in the lower extremities, knees, and hips. 
3.2.5 Genotyping 
Patient DNA was extracted from whole blood in EDTA tubes using either the MagNA 
Pure Compact instrument (Roche, Laval, Quebec, Canada) or the MagMaxTM Express 
instrument (Thermo Fisher Scientific, Waltham, Massachusetts, United States). DNA 
samples were stored at -20°C until analysis. TaqMan® allelic discrimination assays 
(Applied Biosystems, Carlsbad, CA) were performed for the following SNPs: CYP19A1 
(rs4775936, assay ID: C__11301451_10); ESR1 (rs9322336, assay ID: 
C__29568677_10; rs2234693, assay ID: C___3163590_10; and rs9340799, assay ID: 
C___3163591_10); OPG (rs2073618, assay ID: C___1971047_1_); RANKL (rs7984870, 
assay ID: C__29811035_20); and TCL1A (rs11849538, assay ID:  C___1927667_10). 
The Hardy-Weinberg equilibrium was assessed for all genotypes using Chi-square 
goodness-of-fit test. 
3.2.6 Statistical analyses 
All statistical analyses were performed using R (version 3.31)[9] and GraphPad Prism 
(version 6.0, San Diego, CA) statistical software. All tests were two-sided and were 
considered statistically significant at P ≤ 0.05. Logistical regression was performed on 
each SNP using the development of arthralgia and discontinuation of drug as the outcome 
measure, correcting for the clinical variables of age and BMI. The time from initiation to 
discontinuation of AI therapy was compared among the three genotype groups of 
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CYP19A1 using the log-rank test. For patients who did not discontinue treatment, the date 
of the last follow-up inquiry confirming that they were on AI treatment was recorded. 
Cox regression analysis was used to test for an independent contribution of the treatment 
variable. We report the odds ratio (OR) and the corresponding P value for each covariate. 
The odds ratio can be interpreted as the relative risk for development of AI arthralgia and 
discontinuation of AI therapy. 
3.3 Results  
3.3.1 Patient demographics 
The patient (n = 196) characteristics are summarized in Table 3.1. Our study population 
was primarily of Caucasian ethnicity (93.9%, self reported). The median age was 65, and 
all but one patient were 50 years of age or older, and had proceeded through menopause. 
One 31-year-old patient had become menopausal surgically with a total abdominal 
hysterectomy with bilateral salpingo-oophorectomy. All patients were initiated on either 
the standard dose of 2.5mg of letrozole or 1mg of anastrozole with no adjustments in the 
dose. Although exemestane was also available as a therapeutic option, none of the 
patients enrolled in our study were initiated on exemestane. Of the 196 patients, 186 
patients (94.9%) completed at least two months of treatment and returned for a follow-up 
visit and 138 patients (70.4%) completed at least six months of AI therapy and returned 
to the clinic for a second follow-up visit. 
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3.3.2 AI-induced arthralgia and early discontinuation of AI 
treatment 
We measured arthralgia in our population using the AUSCAN and WOMAC 
questionnaires. Of the 196 patients, 104 (53.1%) reported joint pain or stiffness after 
initiation on an AI. The mean scores on all measures of both the AUSCAN and WOMAC 
increased significantly at each follow-up visit (Table 3.2). Of note, there was a positive 
association between BMI and both AUSCAN (P = 0.001, estimate = 0.370 [95% CI, 
0.160 to 0.581]) and WOMAC (P < 0.0001 estimate = 0.872 [95% CI, 0.561 to 1.183]) 
scores at baseline before AI initiation, adjusting for age. However, baseline AUSCAN (P 
= 0.123) and WOMAC (P = 0.490) scores did not predict the development of AI-induced 
arthralgia, after adjusting for age and BMI. Fifty-five patients (28.1%) discontinued AI 
therapy due to intolerable arthralgia, with a median time to discontinuation of 92 days. 
The mean time to discontinuation was 148 days (SE = 16.68). Two additional patients 
discontinued AI therapy for reasons other than arthralgia, including hair loss and mood 
changes. 
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Table 3.1 Patient characteristics 
  
Letrozole Anastrozole Total 
(n = 125) (n = 71) (n = 196) 
Age (Median (Min, Max)) 65 (31, 88) 65 (50, 84) 65 (31, 88) 
BMI (Median (Min, Max)) 
30.1 (20.1, 
52.6)  
28.9 (18.6, 
45.3) 
29.2 (18.6, 
52.6) 
Race/Ethnicity  (N (%)) 
      Caucasian 117 (93.6%) 67 (94.3%) 184 (93.9%) 
   Asian 2 (1.6%) 1 (1.4%) 3 (1.5%) 
   Other 6 (4.8%) 3 (4.3%) 9 (4.6%) 
ER status (N (%)) 
      Positive 125 (100%) 71 (100%) 196 (100%) 
   Negative 0 0 0 
PR status (N (%)) 
      Positive 105 (84.0%) 60 (84.5%) 165 (84.2%) 
   Negative 20 (16.0%) 11 (15.5%) 31 (15.8%) 
HER2 status (N (%)) 
      Positive 16 (12.8%) 10 (14.1%) 26 (13.3%) 
   Negative 109 (87.2%) 61 (85.9%) 170 (86.7%) 
Stage of cancer (N (%)) 
      I (A/B) 38 (30.4%) 34 (47.9%) 72 (36.7%) 
   II (A/B) 67 (53.6%) 33 (46.5%) 100 (51.0%) 
   III (A/B/C) 20 (16.0%) 4 (5.6%) 24 (12.2%) 
   IV 0 0 0 
Prior chemotherapy (N (%)) 
   
   Yes  65 (52.0%) 25 (35.2%) 90 (45.9%) 
   No 60 (48%) 46 (64.8%) 106 (54.1%) 
Prior taxane use (N (%)) 
   
   Yes  60 (48.0%) 21 (29.6%) 81 (41.3%) 
   No 65 (52.0%) 50 (70.4%) 115 (58.7%) 
BMI body mass index; ER estrogen receptor; PR progesterone receptor; HER2 human 
epidermal growth factor receptor 2 
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Table 3.2 Mean questionnaire scores at the three study time points 
  
Baseline  
(n = 196) 
  
Follow-up visit 1  
(n = 186) 
  
Mean 
 
Mean Estimate 95% CI Sig. 
AUSCAN 
           Pain  2.46 
 
3.2 0.83 0.32 to 1.33 * 
     Stiffness 0.76 
 
0.91 0.16 0.02 to 0.29 * 
     Physical functioning 4.39 
 
5.01 0.77 0.01 to 1.52 * 
     Total score 7.61 
 
9.12 1.77 0.55 to 2.98 * 
WOMAC 
           Pain  2.92 
 
3.58 0.74 0.26 to 1.22 * 
     Stiffness 1.59 
 
2.03 0.44 0.20 to 0.68 * 
     Physical functioning 8.90 
 
11.13 2.46 1.14 to3.77 * 
     Total score 13.41   16.74 3.65 1.81 to 5.49 * 
 
 
 
(Table 3.2 continued) 
  
Follow-up visit 2  
(n = 138) 
  Mean  Estimate 95% CI Sig. 
AUSCAN 
         Pain  3.63 1.44 0.87 to 2.00 * 
     Stiffness 1.10 0.37 0.23 to 0.52 * 
     Physical functioning 6.17 2.22  1.37 to 3.06 * 
     Total score 10.90 4.08 2.71 to 5.44 * 
WOMAC 
         Pain  3.95 1.20 0.66 to 1.73 * 
     Stiffness 2.10 0.54 0.28 to 0.81 * 
     Physical functioning 12.21 4.04 2.56 to 5.52 * 
     Total score 18.15 5.80 3.73 to 7.85 * 
AUSCAN Australian/Canadian Osteoarthritis Hand Index; WOMAC Western Ontario and 
McMaster Osteoarthritis Index; CI confidence interval; Sig. Significant. Statistical test: 
linear regression model. All effect estimates are corrected for age, BMI, and genotype. 
Significance indicates that the 95% confidence interval for the effect estimate does not 
cross zero. 
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Table 3.3 Association of arthralgia with clinical variables 
    Univariate analysis 
    
Unadjusted 
P value 
Odds 
Ratio 95% CI 
Intercept  
 
      
Age (years) 0.584 0.990 0.956 to 1.026 
BMI (kg/m2)  0.001 1.088 1.035 to 1.144 
Aromatase inhibitor Letrozole reference   
 Anastrozole 0.023 0.504 0.279 to 0.910 
Prior chemotherapy Yes reference   
 No 0.519 0.831 0.473 to 1.460  
Prior taxane therapy Yes reference 
  
 
No 0.557 0.843 0.476 to 1.491 
Luminal status Luminal A  reference 
  
 
Luminal B 0.241 0.607 0.264 to 1.399 
Cancer stage I (A/B) reference   
 II (A/B) 0.773 1.094 0.596 to 2.008 
  III (A/B/C) 0.556 0.757 0.300 to 1.913 
CI confidence interval; BMI body mass index 
 
 
(Table 3.3 continued) 
    Multivariable analysis 
    
Adjusted 
P value 
Odds 
Ratio 95% CI 
Intercept  
 
0.374 0.255   
Age (years) 0.757 0.993 0.952 to 1.036 
BMI (kg/m2)  0.001 1.088 1.037 to 1.152 
Aromatase inhibitor Letrozole    
 Anastrozole 0.018 0.462 0.244 to 0.877 
Prior chemotherapy Yes reference   
 No 0.720 0.765 0.178 to 3.294 
Prior taxane therapy Yes reference   
 
No 0.970 0.971 0.208 to 4.523 
Luminal status Luminal A  reference   
 
Luminal B 0.285 0.611 0.248 to 1.508 
Cancer stage I (A/B) reference   
 II (A/B) 0.453 0.761 0.372 to 1.555 
  III (A/B/C) 0.276 0.534 0.173 to 1.651 
CI confidence interval; BMI body mass index 
Statistical tests: Logistical and linear regression models. 
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3.3.3 Clinical variables associated with AI arthralgia 
BMI was significantly associated with AI-induced arthralgia (P = 0.001; OR = 1.088 [CI 
95%, 1.025 to 1.144], Table 3.3) and this significance was maintained in the 
multivariable analysis. The odds ratio for this clinical variable was quite small, indicating 
that although this is a precise predictor of arthralgia, it only influences its development to 
a small degree. BMI was not found to be a predictor for discontinuation of therapy (P = 
0.113; OR = 1.039 [CI 95%, 0.991 to 1.090]). The development of arthralgia symptoms 
was significantly less in patients prescribed anastrozole compared to letrozole in both the 
univariate (P = 0.023; OR = 0.504 [95% CI, 0.279 to 0.910], Table 3.3) and multivariable 
analyses (P = 0.018; OR = 0.462 [95% CI, 0.244 to 0.877], Table 3.3). Patients 
prescribed anastrozole were significantly less likely to discontinue their drug due to AI-
induced arthralgia than patients prescribed letrozole (P = 0.032; OR = 0.464 [CI 95%, 
0.230 to 0.934]) after adjusting for age and BMI. The odds ratio indicates that patients on 
letrozole were more than twice as likely to discontinue their AI. 
3.3.4 Pharmacogenetic variables associated with AI arthralgia 
SNP genotyping information is summarized in Table 3.4. Four SNPs, one in CYP19A1 
(rs4775936) and three in ESR1 (rs9322336, rs2234693, rs930799) were significantly 
associated with the development of arthralgia when controlling for the clinical variables 
of age and BMI (Table 3.5). Interestingly, the SNP in CYP19A1 (rs4775936) was 
significantly associated with discontinuation of drug due to arthralgia when controlling 
for age and BMI (Table 3.6). Using a Cox regression analysis, CYP19A1 (rs4775936) 
was also significantly associated with discontinuation of drug due to arthralgia (log 
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ranked P = 0.035, Figure 3.1). The SNPs in selected genes associated with inflammation 
(OPG, TCLA1, RANKL) were not associated with either arthralgia or early 
discontinuation of drug due to arthralgia. Because the results of previous studies on 
RANKL suggested that there might be a recessive effect of the G allele, we repeated the 
genetic association for this SNP using a recessive genetic model, adjusting for age and 
BMI, but did not find that it was associated with AI-induced arthralgia (P = 0.233; OR = 
1.464 [95% CI, 0.782 to 2.738]) or discontinuation of drug (P = 0.170; OR = 1.581 [95% 
CI, 0.822 to 3.041]). 
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Table 3.4 SNP information and genotyping quality control 
Gene rs ID 
SNP location  
or AA 
change Call rate 
MAF  
in this 
cohort 
HWE 
P value 
CYP19A1 rs4775936  Intronic 1.0 0.44 0.338 
ESR1 rs2234693 Intronic 1.0 0.42 0.936 
ESR1 rs9322336 Intronic 1.0 0.24 0.117 
ESR1 rs9340799 Intronic 1.0 0.30 0.300 
OPG rs2073618 Asn3Lys 1.0 0.49 0.569 
TCL1A rs11849538 Downstream 1.0 0.12 0.140 
RANKL rs7984870 Intronic 1.0 0.43 0.560 
SNP single nucleotide polymorphism; MAF minor allele frequency; HWE Hardy–
Weinberg equilibrium 
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Table 3.5 Genetic associations with AI arthralgia 
Gene SNP 
Odds 
Ratio 95% CI P Value Sig. 
CYP19A1 rs4775936 1.719 1.115 to 2.692 0.016 * 
ESR1 rs9322336 0.553 0.336 to 0.896 0.018 * 
ESR1 rs2234693 1.706 1.109 to 2.673 0.017 * 
ESR1 rs9340799 1.626 1.014 to 2.656 0.047 * 
OPG rs2073618 1.107 0.741 to 1.660 0.619 
 TCL1A rs11849538 1.146 0.637 to 2.089 0.649 
 RANKL rs7984870 0.874 0.574 to 1.324 0.525 
 SNP single nucleotide polymorphism; Sig. significance. All associations are corrected for 
age and BMI. Statistical test: logistical regression model. 
 
 
 
 
 
 
 
 
 
 
 
 
 
87 
 
Table 3.6 Genetic associations with early discontinuation of AI 
Gene rs ID 
Odds 
Ratio 
Confidence 
Interval P Value Sig. 
CYP19A1 rs4775936 1.618 1.019 to 2.607 0.044 * 
ESR1 rs9322336 0.633 0.364 to 1.061 0.092 
 ESR1 rs2234693 1.386 0.889 to 2.174 0.151 
 ESR1 rs9340799 1.515 0.924 to 2.498 0.100 
 OPG rs2073618 0.976 0.630 to 1.509 0.912 
 TCL1A rs11849538 1.440 0.781 to 2.607 0.231 
 RANKL rs7984870 0.762 0.480 to 1.194 0.240 
 SNP single nucleotide polymorphism; Sig. significance. All associations are corrected for 
age and BMI. Statistical test: logistical regression model. 
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Figure 3.1 Time to treatment discontinuation for patient-reported AI arthralgia 
CYP19A1 (rs4775936) genotype (C/C, C/T, and T/T). The proportion of patients 
remaining on the first aromatase inhibitor medication is given on the y-axis. AI, 
aromatase inhibitor; OR, odds ratio. Statistical test: Cox regression model. 
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3.4 Discussion 
 
In this prospective analysis of arthralgia in early stage breast cancer patients treated with 
AIs, we observed that more than half of patients developed arthralgia symptoms during 
treatment with AIs. We found that nearly one-third of patients discontinued AI therapy 
due to severe and intolerable musculoskeletal adverse reactions. Our results are consistent 
with previous studies in which compliance to AI therapy was compromised by ADRs, 
primarily musculoskeletal in nature [6, 10]. 
The etiology of AI-induced arthralgia is relatively unclear, although different 
mechanisms and pathways have been identified [8]. Our study focused on mechanism-
specific predictors of AI-induced arthralgia in the estrogen and inflammation pathways. 
CYP19A1 is a gene that encodes aromatase, an enzyme responsible for the biosynthesis of 
estrogen and the protein target of AIs. A study by Garcia-Giralt et al. (2013) found that 
the CYP19A1 SNP rs4775936 was associated with worsened arthralgia pain [11]. In our 
study, we found that rs4775936 was not only associated with arthralgia but also predicted 
early discontinuation of AI therapy due to arthralgia. SNPs in ESR1 (rs9322336, 
rs2234693, rs930799) also have been found to be associated with the development of AI-
related musculoskeletal symptoms [12, 13]. ESR1 is a gene which encodes estrogen 
receptor alpha (ER-α), which is an estrogen-activated transcription factor. ER-α is the 
primary receptor in the estrogen signalling pathway, and its expression is the defining 
feature of ER-positive breast cancer [14]. The intronic variant in ESR1 (rs9322336) was 
found to be associated with AI-induced arthralgia in patients treated with exemestane 
[12]. Although our population was treated with letrozole and anastrozole only, we found 
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that rs9322336 was associated with the development of arthralgia, indicating that this 
SNP might predict arthralgia for all three AIs. 
We were unable to validate previously reported findings that demonstrated that a SNP 
(rs11849538) near the TCL1A gene was associated with a decrease in arthralgia. This 
SNP was identified in a genome-wide association study of breast cancer patients in the 
MA.27 phase III clinical trial. Previous pharmacogenetic studies of RANKL (rs7984870) 
demonstrated that the G allele was protective of AI-induced arthralgia [15], and patients 
homozygous for the G allele of rs7984870 in RANKL had a lower risk of musculoskeletal 
ADR-associated treatment discontinuation [16]. The rs7984870 SNP was not 
significantly associated with arthralgia or discontinuation of therapy in our population 
when using either an additive genetic model or a recessive genetic model. OPG 
(rs2073618) is a missense Asn3Lys SNP that was originally found to be associated with 
decreased OPG expression and an increased risk of musculoskeletal ADRs in a 
population of breast cancer patients treated with AIs in a Chinese Han population [15]. A 
recent study was unable to replicate this association between rs2073618 and the 
development of musculoskeletal symptoms [16], which is consistent with our findings 
that there is no association between OPG (rs2073618) and the development of AI-
induced arthralgia. 
It was interesting to note that the clinical variable of BMI was significantly associated 
with the development of arthralgia, although the odds ratio was small, indicating that the 
impact of the variable is of lower importance. BMI has been previously linked to 
increased estrogen levels, as aromatase catalyzes biosynthesis of estrogen in the adipose 
tissues of post-menopausal women [5]. 
91 
 
We observed a significant difference in tolerability between letrozole and anastrozole in 
our population. However, a large meta-analysis of clinical trial data detected no 
difference in musculoskeletal ADRs among patients treated with any of the three AIs 
[17]. However, a prospective study evaluating musculoskeletal symptoms in early-stage 
breast cancer patients treated with exemestane or letrozole found that time to treatment 
discontinuation was significantly shorter in patients prescribed exemestane [10]. It is 
possible that if the effect size between drugs were relatively small, it might not be 
detected in a meta-analysis and would require a study with more sensitive assessment 
tools of musculoskeletal symptoms. This finding requires further replication in order to 
determine whether it has clinical importance. 
A previous study reported that patients who had been previously treated with taxane were 
more likely to report arthralgia symptoms [6]. However, two subsequent studies failed to 
replicate this finding [18, 19]. We also observed that prior treatment with taxane did not 
predict the development of AI-induced arthralgia. 
In summary, more than half of our patients experienced treatment-emergent arthralgia 
symptoms, and almost one-third of our patients discontinued their AI treatment due to 
arthralgia. Both clinical and genetic factors help to explain the variation in tolerability of 
AIs. We replicated previously established associations of SNPs in genes within the 
estrogen-signalling pathway. Additional functional validation studies could aid in 
understanding the mechanism behind these genetic associations and lead to more accurate 
predictors of toxicity. Overall, our findings help to refine interventions to prevent AI-
induced arthralgia and improve compliance with AI therapy. 
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4 PROSPECTIVE ANALYSIS OF VITAMIN D LEVELS, 
VITAMIN D RECEPTOR POLYMORPHISMS, AND 
ARTHRALGIA IN POSTMENOPAUSAL WOMEN ON 
AROMATASE INHIBITORS 
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4.1 Introduction 
Arthralgia pain, characterized by bilateral aches and pains affecting the shoulder, elbow, 
hand, hip and knee joints, is a frequent adverse drug reaction (ADR) among women 
prescribed AIs for treatment of estrogen receptor (ER) positive breast cancer [1-3]. The 
cause of AI arthralgia is unknown, however experts in the field theorize there may be 
multiple contributing factors, including vitamin D levels and SNPs in genes involved in 
the vitamin D metabolic pathway [4]. 
Vitamin D is a hormone that can be synthesized in the skin in the presence of ultraviolet-
B light or consumed orally through supplementation of natural and fortified food [5]. 
Serum 25-hydroxyvitamin D [25(OH)D] provides the most accurate assessment of 
vitamin D status and is used as a biomarker in studies which measure vitamin D [6]. 
Vitamin D metabolism is illustrated in Figure 4.1.  
Like other hormones, vitamin D plays a role in a wide range of processes in the body, 
including musculoskeletal health. Vitamin D deficiency is common in populations north 
of latitude 40 degrees north, in healthy postmenopausal women [7], and in women 
receiving adjuvant chemotherapy for breast cancer [8]. Low vitamin D intake and low 
25(OH)D have been linked to higher prevalence of musculoskeletal symptoms, including 
arthralgia, in populations without breast cancer [9]. Vitamin D has been shown to play a 
role in the development of AI-induced arthralgia. Some studies have found that patients 
with low levels of vitamin D were more likely to develop arthralgia post-initiation on AI 
therapy. One study observed that patients on AIs with musculoskeletal symptoms were 
more likely to be vitamin D deficient at the time of AI initiation when compared to  
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Figure 4.1 Schematic diagram of steroid and vitamin D signalling pathway 
Sterol 27-hydroxylase (encoded by CYP27A1) and vitamin D 25-hydroxylase (encoded 
by CYP2R1) both convert vitamin D2 and D3 to 25-hydroxyvitamin D (calcidiol). 1-α-
hydroxylase (encoded by CYP27B1) catalyzes the hydroxylation of 25(OH)D (calcidiol) 
to the bioactive form 1,25(OH)2D (calcitriol). Calcitriol binds to the vitamin D receptor 
(encoded by VDR) 
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asymptomatic patients [10]. Servitja et al. found that vitamin D levels were closely 
related to the intensity of the arthralgia, with the most severely affected patients having 
the lowest vitamin D levels [11]. Body mass index (BMI) is a clinical factor which has 
been previously shown to be inversely associated with serum 25(OH)D levels [12, 13]. 
Low serum 25(OH)D levels are relatively common in adults over the age of 65 [14]. 
More research is needed to elucidate how these different factors interact to create painful 
joints in patients on AIs. 
SNPs in genes in the vitamin D pathway have been previously investigated in genetic 
association studies in patients on AIs. Garcia-Giralt et al. demonstrated that variants in 
VDR, and CYP27B1 genes predict the risk of AI arthralgia [15]. While vitamin D levels 
are known to impact the development of arthralgia, it is unclear how vitamin D levels, 
genetic variation, and arthralgia interact.  
In our prospective study of women initiated on AI therapy, we investigated the effect of 
genetic variants in the vitamin D pathway, their effect on 25(OH)D levels, and whether 
either of these two factors contributed to the development of AI arthralgia in patients with 
ER-positive breast cancer.  
4.2 Materials and Methods 
4.2.1 Study population 
196 postmenopausal breast cancer patients diagnosed with stage I-III ER-positive breast 
cancer who were considering AI therapy were enrolled at the London Regional Cancer 
Program in London Ontario from April 2015 – December 2017.  All study participants 
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provided written informed consent. The Research Ethics Board at the University of 
Western Ontario approved the study.  
4.2.2 Sample collection and storage 
Blood samples were obtained from each patient at three time points: prior to AI therapy 
initiation, approximately 2 months post-initiation, and 6 months post-initiation on 2.5mg 
of letrozole or 1mg of anastrozole. Date and time of blood collection and last AI dose 
were recorded and used to calculate the time (in hours) since the last dose. Blood samples 
were immediately stored at 4°C before centrifugation at 2000G for 10 minutes for plasma 
isolation. Plasma samples were stored at -80°C until analysis.  
4.2.3 Plasma vitamin D measurement 
Plasma 25-hydroxy-Vitamin D (D2 and D3) levels were measured by ELISA as per 
manufacture’s protocol (BioVendor, Candler, NC). Dates of blood draw for each patient 
were categorized into seasons: Winter (October-March) when the sunlight levels are 
lower and summer (April to September) when sunlight levels are higher.  
4.2.4 Clinical data collection 
Patient demographics including age, height, weight, ethnicity, and medication history 
were documented at the time of the first blood draw, and the letrozole start date was 
recorded. Cancer stage, as well as estrogen receptor (ER), progesterone receptor (PR), 
and HER2 status were collected from the patients’ chart.  
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4.2.5 Instruments 
Patients were asked to complete two musculoskeletal questionnaires – AUSCAN version 
3.1 and the WOMAC version 3.1, which were previously validated as sensitive measures 
for AI-induced arthralgia[16]. The AUSCAN is a 15-item questionnaire assessing pain, 
stiffness, and physical function in the upper body extremities, with possible scores 
ranging from 0-20 for pain, 0-4 for stiffness, and 0-36 for physical function [17]. The 
WOMAC is a 24-item questionnaire that assesses pain, stiffness, and physical function in 
the lower extremities, with possible scores ranging from 0-20 for pain, 0-8 for stiffness, 
and 0-68 for physical function [17]. For both instruments and their subscales, higher 
scores represent worse symptoms. The two questionnaires were administered to each 
patient on three separate occasions and completed at the time of each of the three blood 
draws: prior to AI therapy initiation, approximately 2 months post-initiation, and 6 
months post-initiation.  
4.2.6 Genotyping 
DNA was extracted from whole blood using either a standard DNA extraction protocol 
(QIAmp DNA Mini Kit, Qiagen, Valencia, California) or the MagNA Pure Compact 
instrument (Roche, Laval, Quebec, Canada) and DNA samples were stored at -20°C until 
analysis. VDR (rs11568820, assay ID: C___2880808_10) and CYP27B1 (rs4646536, 
assay ID: C__25623453_10) Taqman allelic discrimination assays (Applied Biosystems, 
Carlsbad, CA) were used for genotyping. Hardy-Weinberg equilibrium was assessed for 
all genotypes using the chi-square goodness-of-fit test.   
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4.2.7 Statistical analysis 
All statistical analyses were performed using R (version 3.31)[18] and GraphPad Prism 
(version 6.0, San Diego, CA) statistical software. All tests were two-sided and were 
considered statistically significant at P ≤ 0.05. 
4.3 Results 
4.3.1 Patient demographics and medication history 
196 postmenopausal women with breast cancer were enrolled into our study prior to 
initiation on AI therapy with patient demographics and medication history summarized in 
Table 4.1. Women were predominantly Caucasian (93.6%). The median age was 66 years 
and the mean age was 65 years (SD = 8.1; range = 31 - 88). All patients were initiated on 
the standard dose of 2.5mg of letrozole (n = 125) or 1mg of anastrozole (n = 71), with no 
adjustments in the dose. In our study, 186 patients (94.9%) completed at least 2 months 
of treatment returned for a follow-up 1 visit and 138 patients (70.4%) completed at least 6 
months of AI therapy and returned to the clinic for a follow-up 2 visit.  
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Table 4.1 Patient characteristics 
  
Total 
(n = 196) 
Age (Median (Min, Max)) 65 (31, 88) 
BMI (Median (Min, Max)) 29.2 (18.6, 52.6) 
Race/Ethnicity  (N (%)) 
    Caucasian 184 (93.9%) 
   Asian 3 (1.5%) 
   Other 9 (4.6%) 
ER status (N (%)) 
    Positive 196 (100%) 
   Negative 0 
PR status (N (%)) 
    Positive 165 (84.2%) 
   Negative 31 (15.8%) 
HER2 status (N (%)) 
    Positive 26 (13.3%) 
   Negative 170 (86.7%) 
Stage of cancer (N (%)) 
    I (A/B) 72 (36.7%) 
   II (A/B) 100 (51.0%) 
   III (A/B/C) 24 (12.2%) 
   IV 0 
BMI body mass index; ER estrogen receptor; PR progesterone receptor; HER2 human 
epidermal growth factor receptor 2 
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4.3.2 Vitamin D analysis 
At the baseline visit, the median 25(OH)D level was  29.43ng/ml (10.11 – 84.26 ng/ml, 
25.23 – 210.31nmol/l). One hundred women (51.0%) had vitamin D deficiency (<30 
ng/ml, 75nmol/l); an additional 85 (43.3%) had vitamin D insufficiency (30 – 49 ng/ml; 
75 – 125nmol/l). Only 5.6% of the women had levels that met sufficiency criteria (>50 
ng/ml, >125nmol/l). Vitamin D levels are summarized in table 4.2. We did not observe a 
significant effect of season (summer versus winter) on baseline 25(OH)D level (P = 
0.617, (Figure 4.2).  BMI was significantly associated with vitamin D levels (P < 0.0001, 
estimate = -0.528, Figure 4.3). Interestingly, we found a significant association between 
the development of arthralgia and vitamin D sufficiency. Patients with a 25(OH)D level 
of at least 50ng/ml (>125nmol/l) were four times less likely to develop AI arthralgia, 
adjusted for age, BMI, and genotype (P = 0.048, estimate = 0.263 [95% CI, 0.070 to 
0.988]). 
4.3.3 Pharmacogenetic analysis 
Genotyping information is summarized in Table 4.3. We found that there was a 
significant association between CYP27B1 (rs4646536) and an increase in arthralgia score 
at both follow-up visit 1 (P =0.010, estimate = -2.338 [95% CI, -4.104 to -0.572], Table 
4.4) and follow-up visit 2 (P = 0.043, estimate = -2.588 [95% CI, -5.097 to -0.080, Table 
4.4]). We did not find that CYP27B1 (rs4646536) was significantly associated with early 
discontinuation of drug. We also did not find an association with VDR (rs11568820) and 
the development of AI arthralgia or early discontinuation of drug 
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Table 4.2 Vitamin D levels 
  
Baseline 
(n = 196) 
Visit 1 
(n = 188) 
Visit 2 
(n = 145) 
Median (ng/ml) 29.43 31.52 35.19 
Minimum (ng/ml) 10.11 8.99 9.79 
Maximum (ng/ml) 84.26 95.54 89.81 
Mean (ng/ml) 30.95 32.47 35.51 
Standard Deviation 11.89 12.12 12.44 
Deficient (n (%)) 100 (51.0%) 81 (43.1%) 49 (33.8%) 
Insufficient (n (%)) 85 (43.4%) 91 (48.4%) 79 (54.6%) 
Sufficient (n (%)) 11 (5.6%) 16 (8.5%) 17 (11.4%) 
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Figure 4.2 Frequency distribution of patients' serum 25(OH)D levels 
Levels of 25(OH)D were not significantly different during the winter (blue) than during 
the summer (orange) 
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Figure 4.3 Serum 25(OH)D is negatively associated with BMI 
Effect estimate = -0.528, P < 0.0001. Solid line linear regression line; dotted lines 95% 
confidence intervals. Statistical test: Linear regression model. 
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Table 4.3 SNP information and genotyping quality control (n = 196) 
Gene rs ID 
SNP 
location  
or AA 
change Call rate 
MAF  
in this 
cohort 
HWE 
P value 
VDR rs11568820 Upstream 1.0 0.20 0.533 
CYP27B1 rs4646536 Intronic 1.0 0.32 0.836 
SNP single nucleotide polymorphism; MAF minor allele frequency; HWE Hardy–
Weinberg equilibrium 
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Table 4.4 Genetic associations with change in AUSCAN and WOMAC score 
      AUSCAN   
Gene 
name rs number 
Follow-up 
 visit Estimate P value 95% CI Sig. 
VDR rs4646536 1 0.823 0.438  -1.268 to 2.915 
 
  
2 1.512 0.486  -4.048 to 1.936 
 
       CYP27B1 rs11568820 1 -2.338 0.010  -4.104 to -0.572 * 
    2 -2.588 0.043  -5.097 to -0.080 * 
AUSCAN Australian/Canadian Osteoarthritis Hand Index; WOMAC Western Ontario and 
McMaster Osteoarthritis Index; CI confidence interval Sig. Significant. Statistical test: 
logistical regression 
 
Table 4.4 continued 
      WOMAC   
Gene 
name rs number 
Follow-up 
 visit Estimate P value 95% CI Sig. 
VDR rs4646536 1 0.223 0.878  -2.649 to 3.096 
 
  
2 -0.334 0.883  -4.830 to 4.162 
 
       CYP27B1 rs11568820 1 -1.759 0.159  -4.212 to 0.695 
     2 -2.083 0.281  -5.888 to 1.723   
AUSCAN Australian/Canadian Osteoarthritis Hand Index; WOMAC Western Ontario and 
McMaster Osteoarthritis Index; CI confidence interval Sig. Significant. Statistical test: 
logistical regression 
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4.4 Discussion 
In our study, patients with serum 25(OH) vitamin D level of greater than 50ng/mL were 4 
times less likely to develop arthralgia. Previous studies have investigated this as a 
potential intervention and have reported conflicting results. A double-blind placebo-
controlled randomized study was performed with 60 women who were taking anastrozole 
to establish whether vitamin D supplementation could improve the symptoms of AI-
induced arthralgia. The study found that weekly high dose (50,000 IU) vitamin D 
significantly improved musculoskeletal symptoms in patients on AIs [19]. A subsequent 
study of 160 patients on a weekly dose of 30,000 IU of vitamin D did not demonstrate a 
decrease in musculoskeletal symptoms [20]. In this study, patients in the vitamin D 
treatment arm reached a median dose of 53.0ng/mL, [range = 25.2 to 81.0ng/mL] at week 
12 and 64ng/mL (range 23.0 to 87.0ng/mL). There was a significant portion of the 
treatment group that did not achieve 50ng/mL (>125nmol/l) levels on 30,000IU. It is 
possible that a higher dose to ensure the 25(OH)D level is above 50ng/ml is required to 
see a therapeutic effect. The patients in other studies which have found a positive effect 
of vitamin D supplementation on AI arthralgia achieved serum 25(OH)D levels of greater 
than 50ng/ml [21]. We found that CYP27B1 (rs4646536) was associated with an increase 
in score on the AUSCAN scale, indicating worsening pain, stiffness, and physical 
function in the hands, arms, and shoulders. We did not replicate previous findings by 
Garcia-Gault that VDR (rs11568820) was associated with worsening musculoskeletal 
symptoms. Furthermore neither SNP was associated with discontinuation of drug. 
Vitamin D levels in our patients were not associated with either SNP, and 25(OH)D was 
not a significant covariate when we added it into multivariable models with either of 
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these SNPs. We did not observe a significant association between season and vitamin D 
level, however this may be due to sample size. Several studies have identified a seasonal 
impact on vitamin D level due to the changing levels of sunlight exposure, however these 
studies need to be quite large in order to detect this effect [22]. In conclusion, our finding 
suggest that sufficient vitamin D supplementation to reach a plasma level greater than 
50ng/mL (>125nmol/l) could be a therapeutic strategy to help prevent AI arthralgia. 
Further research is needed to establish the vitamin D dose that is required to consistently 
produce this level in all patients, and to define other clinical variables, such as BMI, 
which may influence vitamin D level. 
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5 DISCUSSION AND CONCLUSIONS 
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5.1 Summary and Discussion 
5.1.1 Chapter Four 
The aromatase inhibitor letrozole is a first-line drug in the adjuvant treatment of breast 
cancer in postmenopausal women. Adherence to AI therapy, including letrozole, remains 
problematic due to the development of debilitating AI-associated arthralgia. Letrozole is 
metabolized in the liver by CYP2A6. The aim of Chapter Four was to determine whether 
plasma letrozole levels or CYP2A6 genetic variation is associated with the development 
of arthralgia. We hypothesized that genetic polymorphisms in CYP2A6 were associated 
with altered letrozole plasma levels and arthralgia. 
 
More than half of patients experienced a significant increase in their arthralgia symptoms. 
The clinical variables body mass index and age were negatively and positively associated 
with plasma letrozole concentrations, respectively. CYP2A6 genotype was significantly 
associated with letrozole levels and increased plasma letrozole levels were observed in 
patients with CYP2A6 reduced-function genotypes. We found that letrozole drug level 
and CYP2A6 genotype were not significantly associated with a change in pain score from 
baseline. From our studies, we demonstrate that letrozole concentration is not responsible 
for the development of AI arthralgia. A prospective study of patients on exemestane and 
letrozole did not detect differences between steady-state drug concentrations and patient-
reported quality of life outcomes or treatment discontinuation [1]. Though maintaining 
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systemic drug concentrations within a therapeutic range is essential for some drugs, this 
does not appear to be the case for AIs.  
5.1.2 Chapter Five 
Female patients with breast cancer develop arthralgia when treated with AIs. Though the 
mechanism of AI arthralgia is unknown, clinical factors and potential biomarkers have 
been identified that may predict their development. Replication and validation of these 
biomarkers are an essential next step to move these discoveries into implementation in 
patient care. The aim of this chapter was to investigate the clinical and genetic predictors 
of AI arthralgia in a prospective cohort of patients with estrogen receptor-positive breast 
cancer. We hypothesized that SNPs previously identified by genetic screens and genome-
wide association studies would be significantly associated with arthralgia and early 
discontinuation of therapy in our population.  
 
Of the 196 women, more than 50% experienced arthralgia symptoms. Genetic analysis 
revealed that four SNPs, in CYP19A1 (rs4775936) and ESR1 (rs9322336, rs2234693, 
rs930799), were associated with the development of arthralgia. BMI was also associated 
with the development of arthralgia symptoms compared to baseline. Patients prescribed 
letrozole were significantly more likely to develop arthralgia than patients on anastrozole, 
and also more likely to discontinue AI therapy due to arthralgia. One SNP, in CYP19A1 
(rs4775936), and BMI were significantly associated with discontinuation of drug due to 
intolerable arthralgia.  
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Our results suggested that BMI and AI drug (letrozole versus anastrozole) were clinical 
predictors of arthralgia, while genetic variants rs4775936, rs9322336, rs2234693, and 
rs930799 were the genetic predictors of AI arthralgia. Significantly, rs4775936 is also a 
predictor of discontinuation of drug.  
5.1.3 Chapter Six 
In Chapter Six, we hypothesized that the vitamin D pathway played a vital role in the 
development of arthralgia. The aim of this chapter was to attempt a replication of 
previously identified genetic predictors of AI arthralgia. We hypothesized that genetic 
variants in the vitamin D signalling and metabolism pathway and serum 25-
hydroxyvitamin D [25(OH)D] levels contribute to the development of AI arthralgia in 
patients with ER-positive breast cancer. We found that a SNP in CYP27B1 previously 
identified in a candidate gene study was significantly associated with of pain, stiffness, 
and worsening physical functioning in the hands, arms, and shoulders. We also found 
evidence suggesting that a [25(OH)D] level of 50ng/ml or greater is protective against the 
development of AI arthralgia.  
5.2 Therapeutic Interventions 
To our knowledge, this is the first data set of its kind to prospectively measure AI-
arthralgia using the AUSCAN and WOMAC, while also collecting genotypic, clinical, 
and drug level data in patients on AIs. Our studies revealed that the AUSCAN and 
WOMAC were sensitive measures of AI arthralgia. The use of the AUSCAN and the 
116 
 
WOMAC may be applied in clinical practice to help clinicians assess patient 
musculoskeletal symptoms. 
In addition, we demonstrated that a serum 25(OH)D level of 50ng/ml was the threshold at 
which the patients were 4 times less likely to develop AI arthralgia. Combined with 
findings from other vitamin D randomized clinical trials [2, 3], these data support vitamin 
D supplementation as an intervention to try to prevent AI arthralgia. Next steps could 
include a vitamin D randomized clinical trial with the goal of achieving at least 50ng/ml 
serum 25(OH)D level.  
5.3 Limitations 
We were enrolling patients from one hospital site in London, Ontario. This meant that our 
patient population predominantly Caucasian and we were somewhat limited in our 
sample size. Though we enrolled sufficient patients based on our power calculations, it 
would be interesting to include a greater number of patients in the future. 
Enrolling patients in a busy clinic environment meant that it was not feasible to conduct 
an extensive battery of tests that may measure different aspects of arthralgia. Because of 
this, we selected previously validated questionnaires to measure pain, stiffness, and 
physical functioning. However, a limitation is that we could have used other measures, 
such as a 6-minute walk test and grip strength tests to measure arthralgia in our patients.  
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5.4 Future Directions 
Collaborating with other Canadian, U.S., and international cancer centers would allow us 
to expand the study population and examine more patients from different ethnic 
backgrounds.  
Other future studies could employ the use of a greater number of assessments in order to 
measure pain, stiffness, and physical functioning in patients in addition to the AUSCAN 
and WOMAC questionnaires. The 6-minute walk test or grip strength test could be added 
in order to further measure arthralgia in our patients. Previous studies have utilized 
magnetic resonance imaging (MRI) of hands and wrists to measure tenosynovial changes 
and intra-articular fluid in patients with AI induced arthralgia [4]. If more funding were 
available, it would be interesting to perform MRI on the hands, wrists, and other joints at 
baseline and follow-up appointments. 
It is essential that we have a better understand the mechanisms underlying the 
associations with SNPs identified in our studies. Further in vitro investigations of 
estrogen metabolism and estrogen signalling could help to better understand the 
mechanism underlying AI arthralgia.  
5.5 Conclusions 
There is a growing recognition of the role of genetic factors in the development of 
adverse drug reactions and that genetic variability can predict drug response. The focus of 
this thesis was aromatase inhibitors, an important group of endocrine therapy drugs used 
to treat breast cancer in post-menopausal women. We focused on validating previously 
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identified molecular and genetic biomarkers. We also examined the role of different 
pathways that underlie the mechanism of AI arthralgia. Taken together, these studies 
increase our understanding of AI arthralgia and improve our ability to predict variability 
in the pharmacokinetics of and response to aromatase inhibitors.  
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Appendix C - Australian Canadian Osteoarthritis Hand Index 
 
AUSCAN Survey ID Number:    
 
Instructions: In Sections A, B, and C, questions will be asked about your shoulder, arm or hand pain. Please mark each 
response with an X. If you are unsure about how to answer a question, please give the best answer you can. 
 
 
A. Think about the pain you felt in your shoulders/arms/hands during the last 48 hours. 
Question: How much pain do you have? 
 
1. At rest 
 
2. Gripping objects with your hands 
 
3. Lifting objects 
 
4. Turning objects 
 
5. Squeezing objects 
 
None Mild Moderate   Severe   Extreme 
 
 
B. Think about the stiffness (not pain) you have in your shoulders/arms/hands during the last 48 hours. Stiffness is a sensation 
of decreased ease in moving your joint. 
None Mild Moderate Severe Extreme 
 
6. How severe is your stiffness after first awakening in the morning? 
 
 
 
C. Think about the difficulty you had in doing the following daily physical activities due to your shoulders/arms/hands during the 
last 48 hours. By this we mean your ability to move around and look after yourself. 
 
Question: What degree of difficulty do you have? 
 
7. Turning tap/faucets on 
 
8. Turning a round doorknob or handle 
 
9. Doing up buttons 
 
10. Fastening jewelry 
 
11. Opening a new jar 
 
12. Carrying a full pot with one hand 
 
13. Peeling vegetables/fruits 
14. Picking up large heavy objects 
15. Wringing out wash cloths 
 
 
 
 
 
 
 
 
 
 
 
None Mild Moderate Severe Extreme 
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Appendix D - Western Ontario and McMaster Universities Arthritis Index 
 
WOMAC Survey ID Number:    
 
Instructions: In Sections A, B, and C, questions will be asked about your hip or knee pain. Please mark each response with an 
X. If you are unsure about how to answer a question, please give the best answer you can. 
 
A. Think about the pain you felt in your hip/knee during the last 48 hours. 
Question: How much pain do you have? 
 
1. Walking on a flat surface 
 
2. Going up and down stairs 
 
3. At night while in bed, pain disturbs your sleep 
 
4. Sitting or lying 
 
5. Standing upright 
 
None Mild Moderate   Severe   Extreme 
 
 
B. Think about the stiffness (not pain) you have in your hip/knee during the last 48 hours. Stiffness is a sensation of decreased 
ease in moving your joint. 
None Mild Moderate Severe Extreme 
 
6. How severe is your stiffness after first awakening in the morning? 
 
7. How severe is your stiffness after sitting, lying, or resting in the day? 
 
 
C. Think about the difficulty you had in doing the following daily physical activities due to your hip/knee during the last 48 hours. 
By this we mean your ability to move around and look after yourself. 
 
Question: What degree of difficulty do you have? 
 
8. Descending stairs 
 
9. Ascending stairs 
 
10. Rising from sitting 
 
11. Standing 
 
12. Bending to the floor 
 
13. Walking on flat surfaces 
 
14. Getting in and out of a car, or on or off a bus 
15. Going shopping 
16. Putting on your socks or stockings 
 
17. Rising from the bed 
 
18. Taking off your socks or stockings 
19. Lying in bed 
 
20. Getting in or out of the bath 
 
21. Sitting 
 
22. Getting on or off the toilet 
23. Performance heavy domestic duties 
24. Performing light domestic duties 
 
None Mild Moderate Severe Extreme 
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